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Glioblastoma remains a fatal neoplasm regardless of recent advances in 
understanding the signalling pathways that fuel this devastating disease. Sustained 
angiogenesis and marked immunosuppression are major features of glioblastoma, and 
approaches targeting these pathways have been regarded as promising. The 
transforming growth factor (TGF)-β and vascular endothelial growth factor (VEGF) 
pathways drive key overlapping functions in glioblastoma biology, such as 
angiogenesis, immunosuppression, stem cell maintenance and invasion. In part I of 
the thesis, we investigated whether TGF-β pathway can act as an escape pathway 
during anti-angiogenic therapy, substituting for VEGF activity. We found that TGF-β is 
an up-stream regulator of VEGF whereas VEGF pathway activity does not alter TGF-
β pathway in vitro. In vivo, single agent activity was observed for the VEGF antibody 
B20-4.1.1 (B20) in three, and for the TGF-β receptor I antagonist LY2157299 (LY) in 
two of four models. Reduction of tumor volume and blood vessel density, but not 
induction of hypoxia, correlated with benefit from B20. Reduction of SMAD2 
phosphorylation by LY2157299 was seen in all models, but did not predict survival. 
Resistance to B20 was associated with gene expression pathways attributed a role in 
anti-angiogenic therapy escape whereas resistance to LY2157299 was associated 
with different immune response gene signatures in SMA-497 and GL-261 gliomas. The 
combination of B20 with LY2157299 was ineffective against SMA-497, but provided 
prolongation of survival in GL-261, associated with early suppression of pSMAD2 in 
tumor and host immune cells, prolonged suppression of angiogenesis, and delayed 
accumulation of tumor-infiltrating microglia/macrophages. These findings highlight the 
complex heterogeneity of glioblastoma, and suggest that dual targeting of the TGF-β 
and VEGF pathways may provide a valuable option in subsets of glioblastoma.  
TGF-β also plays a crucial role in glioblastoma-mediated immunosuppression. Several 
studies have demonstrated how TGF-β signalling dampens T cell-mediated effector 
functions, which results in immune escape of gliomas. Therefore, in the second project 
we aimed to investigate whether TGF-β inhibition can boost the efficacy of anti-PD1 
antibodies in experimental glioma models as several studies have highlighted the need 
of targeting multiple pathways to achieve a durable therapeutic effect. Experiments 
with in vitro syngeneic co-culture models of glioma cells and T lymphocytes showed 




linked with increased anti-tumor activity. These findings warrant further investigation of 
dual PD-1 and TGF-β blockade in experimental glioma models in vivo and these 
experiments are currently ongoing in our laboratory. 
In summary, these findings highlight the complexity of glioblastoma and the need of 
targeting multiple pro-tumorigenic features to reach significant clinical improvements 


































Trotz nennenswerter Fortschritte im Verständnis der zugrundeliegenden Signalwege, 
handelt es sich bei Glioblastomen um aggressive Hirntumoren, für die es bis heute 
keine Heilung gibt. Typische Eigenschaften dieses Tumors sind eine kontinuierliche 
Neubildung von Blutgefässen, die sogenannte Angiogenese, und eine erhebliche 
lokale Immunsuppression. Therapieansätze, die zum Ziel haben, die Signalwege 
dieser beiden Prozesse zu hemmen, gelten seit Langem als vielversprechend. In der 
Biologie des Glioblastoms spielen der “Transforming Growth Factor" (TGF)-β- und der 
“Vascular Endothelial Growth Factor" (VEGF)-Signalweg eine wichtige Rolle. Beide 
weisen überlappende Funktionen auf und sind in verschiedene biologische Prozesse 
involviert. Hierzu zählen Angiogenese, Immunsuppression, Erhaltung von 
Stammzelleigenschaften und Vorgänge der Zellinvasion.  
Im ersten Teil der Arbeit wurde untersucht, ob der TGF-β-Signalweg während anti-
angiogener Therapie gegen VEGF alternativ aktiviert wird und somit als eine Art 
Therapie-Fluchtweg dienen könnte. Wir haben durch in vitro Experimente 
herausgefunden, dass TGF-β in der Signalkaskade oberhalb von VEGF steht und die 
VEGF-Expression regulieren kann, wohingegen die Aktivität des TGF-β-Signalweges 
nicht durch VEGF beeinflusst wird. In vivo konnten wir für den gegen VEGF gerichteten 
Antikörper B20-4.1.1 (B20) eine Anti-Tumor-Aktivität in drei von vier, und für den TGF-
β Rezeptor I-Antagonisten LY2157299, in zwei von vier syngenen Mausgliommodellen 
nachweisen. Dabei korrelierten die Reduktion des Tumorvolumens und die 
Blutgefässdichte mit der Sensitivität gegenüber B20, wohingegen in einigen Modellen 
Hypoxie unabhängig von der Behandlung induziert wurde. Die SMAD2-
Phosphorylierung wurden in allen Modellen durch LY2157299 reduziert, war aber kein 
prognostischer Faktor für das Überleben der Mäuse. Anhand von 
Transkriptomanalysen konnten wir zeigen, dass eine Resistenz gegenüber B20 mit 
der Aktivierung eines anti-angiogenen Therapieresistenz-Genexpressionsmusters 
assoziiert ist. Dagegen war die Resistenz gegenüber LY2157299 mit unterschiedlichen 
Immunantwort-Gensignaturen in den SMA-497- und GL-261-Gliommodellen 
verbunden. Im SMA-497-Tumormodell war die Kombination von B20 mit LY2157299 
ineffektiv, dagegen wirkte sie sich positiv auf das Überleben von GL-261 Tumor-
tragenden Mäusen aus. Dieser Effekt war mit einer frühen Suppression der SMAD2-




Angiogenese und einer verspäteten Anreicherung von Mikroglia/Makrophagen im 
Tumor assoziiert. Diese Ergebnisse unterstreichen die Heterogenität von 
Glioblastomen und deuten darauf hin, dass eine duale Hemmung des TGF-β- und 
VEGF-Signalwegs eine vielversprechende Option bei einigen Glioblastom-Subtypen 
sein könnte. 
TGF-β spielt auch eine entscheidende Rolle im Rahmen der Gliom-vermittelten 
Immunsuppression. Im zweiten Teil der Arbeit wollten deswegen wir anhand von 
syngenen Mausgliommodellen herausfinden, ob die Wirksamkeit einer "Immun-
Checkpoint"-Blockade durch die Hemmung von TGF-β verstärkt werden kann. Unsere 
eigenen Daten und die Ergebnisse frührer Studien deuten darauf hin, dass eine 
Hemmung mehrerer tumorspezifischer Signalwege essentiell ist, um einen 
anhaltenden immun-vermittelten Therapieerfolg zu erzielen. 
Experimente mit in vitro Ko-Kulturen aus Gliomzellen und T-Lymphozyten haben 
gezeigt, dass die duale Blockierung des PD-1- und des TGF-β-Signalwegs, die 
Wirksamkeit der T-Effektorzellen erhöht, indem die anti-Tumoraktivität verstärkt wird. 
Diese Beobachtungen erfordern weitere Untersuchungen in experimentellen in vivo 
Mausgliommodellen, die aktuell in unserem Labor stattfinden. 
Zusammenfassend deuten unsere Befunde darauf hin, dass in Glioblastomen eine 
komplexe Interaktion zwischen verschiedenen Signalwegen vorliegt. Basierend auf 
diesen Daten lassen sich möglicherweise kombinierte Therapieansätze entwickeln, die 





















3.1.1 Classification of gliomas and epidemiology 
Gliomas are primary brain tumors that have been classified by the World Health 
Organization (WHO) into four prognostic grades based on histological features of 
malignancy. Grade I tumors, such as pilocytic astrocytomas, appear mainly in children 
and are characterized by slow growth, alteration in the mitogen-activated protein 
kinase (MAPK) pathway and favorable prognosis as they can often be removed by 
resection. Grade II and grade III tumors represent the most frequent gliomas in young 
adults and are distinguished by an infiltrative phenotype in the brain parenchyma and 
frequent mutation of the isocitrate dehydrogenase (IDH) 1 or 2 genes. They typically 
recur and may progress to higher grades of malignancy. Traditionally, these tumors 
were histologically classified as astrocytic, oligodendroglial or mixed oligo-astrocytic 
tumors, but recent advances in molecular profiling allowed for a classification into two 
subtypes. The first, the astrocytic type, is marked by mutations of the genome guardian 
TP53, along with frequent mutations of the α-thalassemia/mental retardation syndrome 
X-linked (ATRX) gene. The second, or oligodendroglial type, is characterized by co-
deletion of chromosomal arms 1p/19q and linked with telomerase reverse transcriptase 
(TERT) promoter mutation. Grade IV tumors, referred as glioblastomas, are the most 
prominent and malignant primary brain tumors, which usually manifest after the fifth 
decade of life. These tumors are associated with a dismal prognosis, infiltrative 
phenotype, microvascular proliferation and extensive presence of pseudopalisading 
necrosis. They are referred as primary when arise de novo and secondary when 
progressed from lower grade tumors (Weller et al., 2015; Louis et al., 2016) (Figure 1). 
Importantly, the progress in the so-called omic-technologies, may lead to a new way 
to classify, and therefore treating, gliomas. This is particularly true for the diffusely 
infiltrative gliomas in adults, which can be subdivided in three major groups that differ 
in their pathogenesis and response to treatment: IDH-mutant, 1p/19q co-deleted 
tumors; IDH-mutant, 1p/19q non co-deleted tumors; and IDH wild-type tumors. 
Accordingly, the assessment of these molecular markers has been included into the 




Epidemiologically, the incidence of neuroepithelial tumors in the US has been 6.6 per 
100’000 persons in the period of time between 2008 and 2012 (Ostrom et al., 2015). 
Around half of the diagnosed tumors were classified as glioblastomas. The incidence 
rate in Northern Europe or United States is about double of the rate found in Japan, 
and the reasons for these regional differences are still unknown. The most important 
risk factor associated with glioblastoma is aging, but the underlying biological reasons 
are also not yet known (Weller et al., 2015)  
 
 
3.1.2 Genetic and molecular signatures of glioblastoma 
In recent years, many studies have described the complexity and heterogeneity of 
human tumors. High-throughput gene expression analysis of tumor samples has 
provided valuable insights into the features of glioblastoma. It is now clear that 
histological evaluation by itself cannot accurately classify the inherent complexity of 
glioblastoma. Consequently, four different molecular signature have been described to 
better classify glioblastomas helping to define patients’ prognosis: classical, 
mesenchymal, proneural and neural (Cancer Genome Atlas Research, 2008; Verhaak 
et al., 2010). Yet, this classification has had no implication on clinical decision making 
so far. 
The classical subtype is characterized by aberrant expression of the epidermal growth 
factor receptor (EGFR) and lacks mutations in the IDH genes and TP53. The 
mesenchymal subtype is featured by mutations of the neurofibromatosis type 1 (NF1) 
Figure 1. Genetic and epigenetic alterations of gliomas.  




and the phosphotensin homolog (PTEN) tumor suppressor genes, and high expression 
of the MET proto-oncogene, and is usually associated with a poorer outcome. The 
proneural subtype is associated with high expression levels of platelet-derived growth 
factor receptor (PDGFR) A expression, and mutations in the IDH and TP53 genes, 
which are usually linked with secondary glioblastoma. Lastly, the neural subtype shows 
an expression signature similar to those of the normal brain tissue, and displays 
expression of several neuronal markers; its existence remains doubtful (Cancer 
Genome Atlas Research, 2008; Verhaak et al., 2010; Vitucci et al., 2011; Reifenberger 
et al., 2014).  
 
3.1.3 Glioblastoma current standard of care 
Gliobastomas are the most aggressive and deadly adult primary brain tumors (Ostrom 
et al., 2015). Although patients are treated with multi-modal approaches, the prognosis 
remains poor with a median survival of 16 months within clinical trial populations 
(Weller et al., 2014). The standard of care for patients below 70 years with newly 
diagnosed glioblastoma is tumor resection as feasible, followed by radiotherapy and 
concomitant and maintenance chemotherapy with the alkylating agent temozolomide 
(TMZ) (Stupp et al., 2005). In patients above 70 years, treatment is based on the O6-
methyl guanine methyl transferase (MGMT) promoter methylation status. 
Hypofractionated radiotherapy (15 doses, 2.66 Gy) alone is used in patients with 
MGMT-unmethylated status whereas in MGMT-methylated patients, combined 
radiochemotherapy or TMZ alone can be used (Malmstrom et al., 2012; Wick et al., 
2012; Perry et al., 2017). For patients with tumors that recur after concomitant 
radiochemotherapy, nitrosureas, alternative TMZ dosing regimens or the anti-vascular 
endothelial growth factor (VEGF) antibody, bevacizumab, are administered depending 
on regional guidelines status (Weller et al., 2014). 
 
3.2 Molecular mechanisms driving the malignant phenotype of glioblastoma 
 
3.2.1 Glioma cell of origin and glioma cancer stem cell theory 
Historically, two main theories have been postulated regarding the origin of tumors: the 
stochastic or clonal evolution model, and the hierarchical model or cancer stem cell 
model. The first theory proposes that all cells within a tumor have the same potential 




within the tumor can acquire new mutations allowing for an increased tumor 
heterogeneity and probability of generating a tumor clone, which can either re-generate 
the entire tumor or resist to therapies. Differently, the cancer stem cell hypothesis 
postulates that tumors bear a rare cell population with stem cell characteristics, which 
is able to resist standard therapies and propagate a heterogeneous progeny through 
its unlimited self-renewal potential (Rich, 2008; Shackleton et al., 2009). To date, the 
second hypothesis seems to be more widely accepted.  
In the brain, neural and glial stem cell progenitors exist and possess multi-potency 
features, and these cells have been indicated as possible glioma cells of origin. In 
mice, these cells have been isolated mainly from the subventricular region, the dentate 
gyrus and the hippocampus, and the subcortical white matter (Gage, 2000; Fukuda et 
al., 2003; Kim and Morshead, 2003). The first evidence in humans of the existence of 
glioma stem cells (GSC) came from a work published by Ignatova et al, where cells 
with stem cells properties were isolated from human glioblastoma samples. These cells 
were highly clonogenic, able to form neuro-spheres, expressed neural stem-cell fate 
determining factors and expressed astroglial and neuronal markers after differentiation 
(Ignatova et al., 2002). Studies by Singh and colleagues demonstrated that GSC are 
significantly enriched in the CD133+ population and able to initiate and propagate 
tumors. The orthotopic injection of only 100 cells was enough to establish tumors in 
non-obese diabetic, severe combined immunodeficient (NOD-SCID) mouse brains 
whereas even 10,000 CD133- cells did not (Singh et al., 2003; Singh et al., 2004). 
CD133 as a marker of stemness remains the most widely used to isolate GCS even 
though its specificity has remained controversial. Since the initial publication of Singh 
et al, several other studies explored the importance and the role of GSC in brain tumor 
pathogenesis and demonstrated that these cells share many similar features with 
neuronal stem cells (NSC). In fact, they can self-renew, give rise to different cell 
lineages, and localize in highly specialized niches (Kim and Morshead, 2003; 
Gilbertson and Rich, 2007). Importantly, the nomenclature “stem cell” referred to 
glioma indicates the features and abilities of this tumor cell population and not the 
function of these cells as “cell of origin” of the tumor. 
An important characteristic of GSC is their ability to be resistant to conventional 
treatment modalities, namely radio and chemotherapy. Indeed, CD133+ cells can 
efficiently activate the DNA damage response (DDR) and are protected from the 




GSC may express high levels of MGMT, which renders them resistant to TMZ 
treatment (Liu et al., 2006; Binello and Germano, 2011; Venere et al., 2014). However, 
this remains controversial as another study showed that TMZ preferentially targets 
GSC in glioblastoma (Beier et al., 2008).  
Some data suggest that GSC reside in vascular niches. Calabrese et al showed that 
brain endothelial cells orchestrate a perivascular niche where they supply critical 
factors to maintain brain tumor cells in a stem cell-like phenotype (Calabrese et al., 
2007). Furthermore, a paper from Bao and colleagues found out that GSC secrete high 
levels of the pro-angiogenic molecule VEGF and a report from Hamerlik et al shed light 
on autocrine VEGF/VEGF receptor (VEGFR)2 signalling in GSC, which can protect 
this population from anti-angiogenic therapies. Of note, silencing of VEGFR2 did not 
only affect VEGF secretion but also stem cell properties and tumorigenicity of GSC 
(Bao et al., 2006; Hamerlik et al., 2012). Lastly, some studies propose GSC as possible 
cells of origin of the tumor endothelium, whereas other suggest that these cells can 
differentiate into pericytes stabilizing vessels and thus supporting tumor growth (Ricci-
Vitiani et al., 2010; Wang et al., 2010; Cheng et al., 2013). All these studies support 
the cancer stem cell model and highlight the importance of GSC in the malignant 
phenotype of glioblastoma.  
 
3.2.2 Glioblastoma-associated signalling pathways 
Several pathways are involved in the malignant phenotype of glioblastoma cells. 
Aberrant expression and function of key proteins belonging to important signalling 
pathways are thought to be responsible for tumor-promoting features such as 
proliferation, survival and invasion.  
 
3.2.2.1 RTK/PI3K/Akt pathway 
The receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K)/Akt pathway can 
regulate a plethora of cellular processes and their deregulation may be crucial for 
glioblastoma initiation and progression. The most frequently mutated RTK in 
glioblastoma is EGFR. EGFR amplification is present in 40% of all glioblastomas and 
deregulated expression in up to 60% (Libermann et al., 1984; Ekstrand et al., 1991; 
Wong et al., 1992). Moreover, amplification of the EGFR gene is often associated with 
the expression of a peculiar receptor variant, EGFR variant III (EGFRvIII), which is 




protein. EGFRvIII is constitutively active and can deliver intense intra-cellular signalling 
due to ineffective receptor endocytocis, recycling and protein degradation via the 
ubiquitination system (Ekstrand et al., 1992; Grandal et al., 2007; Huang et al., 2009).  
Downstream of the RTK, the activation of the PI3K pathway is crucial to activate 
multiple cellular processes, including key tumor cell traits such as survival and motility. 
This pathway can be augmented by activating mutations or amplifications of the PI3K 
subunit alpha (PI3KCA) catalytic subunit, or by homozygous deletion or mutations of 
the PTEN gene, which negatively regulates PI3K functions (Furnari et al., 1998; Kita 
et al., 2007). PTEN deletion or mutation is one of the most common genetic alterations 
in glioblastoma, and it is present in 15 to 40% of all tumors (Li et al., 1997; Cancer 
Genome Atlas Research, 2008). 
Not surprisingly, the Akt serine/threonine kinase family, which is a fundamental hub 
downstream of the RTK/PI3K pathway, is hyper-activated in around 80% of human 
glioblastomas (Haas-Kogan et al., 1998). This report is in line with the finding that 
RTK/PI3K/Akt signalling is deregulated in 88% of human glioblastomas (Cancer 
Genome Atlas Research, 2008).  
 
3.2.2.2 TP53 pathway 
The TP53 pathway is probably the most frequently mutated pathway in cancer. TP53 
protein, also called the genome guardian, responds to many intra- and extracellular 
stimuli, and regulates various processes that control cell cycle progression, DNA 
repair, and apoptosis (Bogler et al., 1995). Disruption of this pathway can occur by 
mutation of the TP53 gene itself, or amplification of the mouse double minute (MDM)-
2 or -4, or deletion/mutations of the p14 alternative reading frame (ARF) gene 
(Reifenberger et al., 1993; Ichimura et al., 2000). Interestingly, mutations of this 
pathway are observed mainly in IDH mutant glioblastomas, with a percentage of 65% 
versus 30% of IDH wild type tumors. Lastly, another mechanism of pathway’s 
disruption is promoter methylation of the p14ARF gene. Indeed, promoter methylation 
or homozygous deletion happens in 50 and 75% of wild type and mutant IDH 
glioblastomas, respectively (Nakamura et al., 2001; Ohgaki and Kleihues, 2009). 
 
3.2.2.3 RB pathway 
The retinoblastoma (RB) pathway is a critical gatekeeper, which regulates cell cycle 




cycle progression, the cyclinD1/cyclin-dependent kinase (CDK) 4 complex can inhibit 
the RB protein by phosphorylation, releasing the molecular break that controls the 
activity of the E2F transcription factor. Once activated, E2F readily accelerates the 
transition from G1 to S phase of the cell cycle. Importantly, the initial cyclinD1/CDK4 
complex can be inhibited by two master tumor suppressors; the CDKN2A (P16INK4a) 
and the CDKN2B (P15INK4b) proteins. Thus, mutations occurring in any of these genes 
can disrupt cell cycle control and lead to unchecked proliferation. The Cancer Genome 
Atlas Network work has unveiled that the RB pathway is deregulated in 77% of 
glioblastomas and the most frequently mutated genes are CDKN2A and CDKN2B, 
which are deleted or mutated in 52 and 47% of the analyzed tumors, respectively 
(Cancer Genome Atlas Research, 2008).  
 
3.3 Angiogenesis in glioblastoma 
 
3.3.1 Mechanisms of brain tumor vessel formation 
In physiological conditions, the normal brain vasculature is highly specialized. The 
blood brain barrier (BBB) is composed of endothelial cells, pericytes, astrocytes and 
perivascular macrophages, which all together form the neurovascular unit (Abbott et 
al., 2006). It finely regulates the access of molecules to the central nervous system 
(CNS), maintains the correct ionic composition of the brain, thereby preserving 
neurons physiological function, and blocks the entrance of undesirable and possibly 
toxic molecules. Conversely, glioblastoma vessels are highly tortuous, permeable and 
bear many abnormalities in endothelial wall, pericyte coverage and basement 
membrane (Plate and Mennel, 1995; Jain et al., 2007a). Moreover, tumor vessels 
within brain tumors have a larger diameter and thicker basement membrane compared 
to those of the normal brain, and harbor peculiar microvasculature structures termed 








Despite the fact that the brain tumor vasculature loses its ability to regulate the 
selective passage of molecules through the BBB, it still partly possesses the 
physiologic function. Indeed, tumors growing in the brain have significantly reduced 
trans-vascular transport compared to the same tumors grown subcutaneously (Yuan 
et al., 1994; Hobbs et al., 1998). It has to be noted nevertheless that magnetic 
resonance imaging (MRI) studies have shown a 20-fold increase in vascular 
permeability between normal and tumoral vessels within the brain (Jain et al., 2007a). 
This highlights that the loss of the BBB function is heterogeneous and spatial, 
conformational, and tumoral cues impact the entire process. The main problem 
associated to heterogeneous vessels leakiness is represented by an unstable blood 
flow, which in turn, can increase interstitial fluid pressure (IFP). An increased IFP is a 
major problem in glioblastoma patients’ care; it increases intracranial edema that can 
be responsible for many complications, and hinders the correct and homogeneous 
delivery of therapeutic drugs (Jain, 1994; Jain et al., 2007b) (Figure 2).  
Figure 2. Brain tumor vasculature. A. Normal vasculature is structurally organized and built to 
provide even nutrient distribution to all surrounding cells. B. Vasculature of a glioma xenograft model 
is highly disorganized and vessels are not anymore finely connected and organized. Vessels are 
displayed in red, red blood cells in blue and cancer cells in green. C. Correlation between vascular 
endothelial growth factor (VEGF) promoter activity in glioblastoma xenograft tumor cells (expressed 
as GFP produced upon VEGF promoter activation) and oxygen and pH levels (Adapted from Jain 





Interestingly, studies by Harold Dvorak’s group have found that in human and mice 
tumors at least 6 different types of vessels can be generated by two main processes: 
angiogenesis and arterio-venogenesis. It has been shown that all six types can be 
recapitulated in normal mouse tissues by adenoviral vector-mediated expression of 
VEGF-A protein, and importantly, 4 out of 6 vessel types become VEGF-independent 
(Nagy et al., 2007; Sitohy et al., 2012). This concept is important since, as already 
mentioned, brain tumor vascular networks are highly heterogeneous and comprise 
different types of vessels. 
To date, six main pathways of vessel formation have been described in glioblastoma. 
Initially, brain tumor cells can co-opt (1) existing normal vasculature (Holash et al., 
1999). While tumors grow, cells compress the endothelium causing a marked vessel 
shrinkage and reduced blood flow (Padera et al., 2004). This process eventually leads 
to the induction of hypoxia, in turn, generating a harsh microenvironment where tumor 
cell clones with the ability to secrete pro-angiogenic factors are selected. These factors 
elicit the generation of new vessels from pre-existing ones, via angiogenic processes 
(2) (Carmeliet and Jain, 2000). Another mechanism, although poorly understood, is the 
formation of a new vascular network through vasculogenesis (3). Glioma cells can 
express stromal-derived factor (SDF)-1 that can recruit bone marrow-derived cells into 
the brain parenchyma. These cells can be incorporated and stabilize nascent vessels 
within the tumor (Aghi et al., 2006; Santarelli et al., 2006). Intussusception (4) is a 
process by which tumor vessels can remodel and expand inside the interstitial tissue 
columns and into the lumen of pre-formed vessels. It has been initially noted in mouse 
models of brain metastasis; however, the underlying molecular mechanisms are still 
unknown (Yano et al., 2000; Nagy et al., 2002). Tumor cells can also fuse into the 
endothelium in a process termed vasculogenic mimicry (5), and GSC have been shown 
to trans-differentiate into endothelial cells (6), which bore peculiar chromosomal 
abnormalities (Ricci-Vitiani et al., 2010; Wang et al., 2010; Carmeliet and Jain, 2011).  
 
3.3.2 Vascular endothelial growth factor signalling pathway 
Dvorak and colleagues discovered the main ligand of this pathway as vascular 
permeability factor (VPF) in 1983. Later on, this factor was termed as VEGF for its 
ability to act as endothelial cell mitogen (Senger et al., 1983; Leung et al., 1989). The 
importance of this gene was highlighted by the observation that the germline deletion 




vascular deficiencies (Carmeliet et al., 1996; Ferrara et al., 1996). Since then, many 
different ligands and splice variants have been discovered, and these can bind with 
different affinities to three VEGFR1-3. In humans, VEGF-A, VEGF-B, VEGF-C, VEGF-
D, and placental growth factor (PlGF) can bind to VEGFR 1-3 and modulate angiogenic 
processes (Maglione et al., 1991; Tammela et al., 2005; Koch et al., 2011) (Figure 3). 
Notably, the VEGF-A gene can undergo alternative splicing mechanisms, which can 
generate many isoforms with different functions. In particular, splicing isoforms 
generated via proximal splice site (PSS) selection in exon 8 (VEGFXXXa) are pro-
angiogenic, whereas those formed from the exon 8 distal slice site (DSS) (VEGFXXXb) 
are weakly angiogenic (Harper and Bates, 2008; Catena et al., 2010).  
VEGFR1 can bind VEGF-A with 10 fold higher affinity than VEGFR2, nevertheless, it 
has a poor tyrosine kinase activity compared to VEGFR2. VEGFR1-/- mice die at day 
9 of the embryonic stage due to a defective vascular system and aberrant endothelial 
proliferation (Fong et al., 1995). Differently, VEGFR2-/- mice have a similar phenotype 
to VEGF knockout mice. These mice die at embryonic day 8.5 due to disrupted 
endothelial and hematopoietic lineage cells development, with consequent severe 
vascular impairments (Shalaby et al., 1995).  
 
3.3.3 VEGF signalling in glioma cells 
VEGF-A is the most important pro-angiogenic factor released by glioma cells. Its 
expression correlates with tumor malignancy and the major transcription factor 
regulating its expression is hypoxia-inducible factor 1α (HIF1α) (Bulnes et al., 2012). 
Interestingly, TP53 that is frequently mutated in glioblastoma, can form transcriptional 
complexes with SP1 thereby inhibiting VEGF-A transcription (Kargiotis et al., 2006). In 
addition, the EGFR signalling pathway, which is hyperactive in around 60% of high-
grade gliomas, can up-regulate VEGF-A expression via MAPK/extracellular signal-
regulated kinase (ERK) pathway (Woods et al., 2002). Notably, EGFRvIII has been 
demonstrated to sustain VEGF expression via Ras-dependent signalling in 
glioblastoma cell lines (Feldkamp et al., 1999).  
VEGF-A plays a fundamental role in the GSC niche, where it regulates survival, 
resistance to therapy, and invasion of GSC (Gorski et al., 1999; Knizetova et al., 2008; 
Hlobilkova et al., 2009; Hamerlik et al., 2012). VEGF-A secreted by tumor cells, can 
also fuel proliferation of tumor associated microglia/macrophage, and promoting 




Furthermore, VEGF-A can act autocrinally on glioma cells themselves, thereby 




3.3.4 Anti-angiogenic therapies in glioblastoma 
VEGF-A represents the most important target of anti-angiogenic therapies for its 
prominent role in physiological and pathological angiogenesis. The first approved drug 
targeting the VEGF-A protein was the humanized monoclonal antibody bevacizumab 
(Avastin). Despite great expectations, two large phase III clinical trials, RTOG 0825 
and AVAGlio, demonstrated a prolongation in progression-free survival, but failed to 
impact overall survival (Chinot et al., 2014; Gilbert et al., 2014). Bevacizumab remains 
a drug of interest for its ability to reduce cerebral edema and to normalize the tumor 
vasculature, which in turn, can relieve IFP and increase the delivery of co-administered 
drugs (Jain, 2005; Gerstner et al., 2009). Another approach is represented by the 
targeting of VEGFR tyrosine kinase activity. The pan-VEGFR inhibitor cediranib was 
shown to normalize the vasculature and to reduce edema in glioblastoma patients 
(Batchelor et al., 2007). Interestingly, analysis of response to cediranib in newly 
diagnosed glioblastoma patients revealed that improved perfusion and tumor 
oxygenation was achieved in a subset of patients associated with improved overall 
survival. The observed improved survival was linked to increased efficacy of 
concomitant chemoradiotherapy and resistance to therapy was associated with post-
Figure 3: VEGF pathway ligands and receptors. The five VEGF pathway ligands, VEGF-A, -B, -
C, -D and PlGF, bind their cognate receptors with different specificities and affinities. Upon binding, 
VEGF receptors can either homo- or –heterodimerize allowing signal transduction into the cell. 
VEGF-C and VEGF-D can bind VEGFR2 only after proteolytic processing. VEGFR2 extracellular 
domain can be cleaved to produce a soluble form. Abbreviations: JMD, juxtamembrane domain; 
KID, kinase insert domain; TMD, transmembrane domain; TKD1, ATP-binding domain; TKD2, 
phosphotransferase domain. 




therapy heightened plasma levels of interleukin (IL)-8 and soluble form of VEGFR1 
(sVEGFR1) (Batchelor et al., 2013). 
Enzastaurin is a protein kinase Cβ (PKCβ) inhibitor, which blocks neo-angiogenesis 
by silencing VEGF transcriptional expression. Yet, clinical trials showed that 
enzastaurin failed to improve overall survival compared to lomustine in recurrent 
glioblastoma (Wick et al., 2010).  
Many other strategies beyond inhibition of the VEGF pathway have been employed. 
Targeting of the mechanistic target of rapamycin (mTOR)/Akt pathway, cMET 
inhibition, integrin inhibition, EGFR and PDGFRβ blockade are all strategies that 
besides targeting tumor cell-core pathways, also affect vessel formation in 
glioblastoma to a different extent (Batchelor et al., 2014). None of these approaches 
significantly changed overall survival of glioblastoma patients. However, anti-
angiogenic agents remain of interest in clinical neuro-oncology, especially to design 
combinatorial strategies aimed at blocking multiple angiogenic pathways. 
 
3.3.5 Resistance to anti-angiogenic therapies 
Resistance mechanisms to anti-angiogenic therapies have been divided in two major 
groups: adaptive resistance and intrinsic non-responsiveness (Figure 4). The former 
occurs when a tumor initially shrinks and regresses due to the therapy, but then 
develops resistance either by adopting new angiogenic pathways to restore the 
vasculature or by becoming less dependent from the targeted factor. The latter occurs 
when the tumor never responded to the therapy and continued growing undisturbed 
(Bergers and Hanahan, 2008). Studies in preclinical models as well as glioblastoma 
patients treated with anti-angiogenic agents have shed light on several escape 
mechanisms. Increased invasiveness of glioblastoma cells has been described as the 
most prominent escape pathway. For example, this escape mechanism has been 
noted in models where factors required for the tumor vasculature, such as HIF-1α, 
matrix metalloproteinase (MMP)-2, and MMP-9, were ablated (Du et al., 2008a; Du et 
al., 2008b). Also, angiogenesis inhibitors or genetic ablation of tumor-derived VEGF-A 
increase invasiveness and progression in a glioblastoma orthotopic model (Paez-
Ribes et al., 2009). Similarly, in a clinically relevant patient-derived xenograft (PDX) 
model, anti-VEGF treatment reduces tumor blood supply, which in turn changes cancer 
cell metabolism, inducing invasion toward normal brain parenchyma (Keunen et al., 




molecules showed that relapsed tumors were highly infiltrative and in one study, this 
was correlated with tumor displaying of mesenchymal markers. However, anti-VEGF-
induced invasiveness remains controversial since other studies have not confirmed 
this assumption (Wick et al., 2011; Soda et al., 2013; Wick et al., 2013). VEGF 
blockade can also induce a more invasive and aggressive tumor phenotype through 
hypoxia-dependent c-MET upregulation and phosphorylation, and in a xenograft 
glioblastoma model via significant increase of mesenchymal markers such as 
transforming growth factor (TGF)-β2 and zinc finger e-box binding homeobox (ZEB)2 
(Lu et al., 2012; Piao et al., 2012b).  A hypoxic microenvironment can increase the 
SDF-1/C-X-C motif chemokine receptor (CXCR)-4 pathway activity, inducing the 
recruitment of pro-angiogenic bone marrow-derived precursors. These cells can drive 
vasculogenic processes to restore radiation-damaged vasculature, and in another 
study, specific deletion of MMP-9 in bone marrow-derived cells impaired the ability of 
the tumor to rebuild vessels lost after irradiation (Kioi et al., 2010; Tseng et al., 2011). 
Hypoxia can also induce an autophagic response in glioblastoma cells in vivo, 
promoting tumor survival and refractoriness to anti-angiogenic treatments. Deletion of 
autophagy related (Atg)7, an essential autophagy gene, prevented tumor resistance to 
bevacizumab (Hu et al., 2012). Another resistance mechanism involves the up-
regulation of other molecules involved in angiogenic processes. Angiopoietin (Ang)-2 
ectopic expression in tumor cells compromises the efficacy of anti-VEGFR2 therapy, 
and in glioblastoma patients up-regulation of fibroblast growth factor (FGF)-2 and SDF-
1 were associated with glioblastoma progression in patients treated with cediranib 
(Batchelor et al., 2007; Chae et al., 2010). From the metabolic perspective, Fack et al 
demonstrated that bevacizumab treatment elicited tumor cell metabolic 
reprogramming toward anaerobic glycolysis. This finding was corroborated by 
subsequent analysis of paired glioblastoma patient biopsies pre- and post-









3.4 Immunosuppression in glioblastoma 
The immune system plays an important role during cancer pathogenesis. Seminal 
studies have shown in methylcholanthrene-induced cancer models that knockout mice 
for key components of the interferon (IFN)-γ pathway or the perforin gene are 
significantly more susceptible to tumor formation (Kaplan et al., 1998; Street et al., 
2001). Later, it became clear that T cells can actively respond to genetic and cellular 
alterations occurring in cancer, and can eliminate arising cancer cells. It has been 
demonstrated that tumor-specific T cells exist against mutated or over-expressed 
tumoral proteins and can respond to these antigens mounting an effector response 
(Coulie et al., 2014). However, the high selective pressure imposed by T cells on 
developing tumors, may eventually lead to immuno-edited clones, which escape from 
immune tumor-surveillance (Dunn et al., 2004). Glioblastoma is paradigmatic for its 
ability to evade immunesurveillance and actively suppresses nascent immune 
responses against the tumor. Major hurdles in the glioblastoma immunotherapeutic 
context are thus the profound local immunosuppression established by glioma cells 
and the location of the tumor within the CNS, which is believed to be immunologically 
privileged.   
Figure 4. General mechanisms of resistance to anti-angiogenic therapies. Adaptive resistance 





3.4.1 Blood brain barrier and principles of neuro-immunology 
The BBB is a highly specialized barrier that regulates molecules and cells entry within 
the CNS. More specifically, this barrier function is achieved through a perpetual 
interaction between the cellular components of the neurovascular unit. Astrocytes are 
fundamental for the maintenance of the endothelium, while pericytes wrap up the 
endothelium preserving its structural stability and have a key role during development 
by inducing endothelium barrier properties (Abbott et al., 2006; Daneman et al., 2010; 
Alvarez et al., 2013; Obermeier et al., 2013). Lastly, perivascular macrophages work 
as scavengers and activators of the immune responses at the barrier interface (Polfliet 
et al., 2001; Serrats et al., 2010). The ability of the endothelium to act as a barrier relies 
on two main features: tight junction proteins and ATP binding cassette (ABC) efflux 
transporters. Tight junctions are key structures to prevent the migration of molecules 
between the endothelial cells forming the BBB. The most important tight junction-
associated proteins present in the BBB are occludin, claudin-1, and claudin-5 (Wolburg 
and Lippoldt, 2002; Abbott et al., 2010). Claudin-1 and occludin are linked through the 
zonula occludens (ZO) protein to other tight junction-associated proteins (e.g. cingulin) 
and to the cellular cytoskeletal system.   
All these complex interactions are critical to generate a tight closure between 
endothelial cells, regulating the passage of substances from the blood compartment to 
the CNS and vice versa (van Tellingen et al., 2015). Differently, ABC transporters 
actively efflux unwanted compounds out of the brain (Pardridge, 2005). The firstly 
discovered and most active ATP transporter is ABCB1 (also known as P-glycoprotein). 
It  mediates multidrug resistance in tumor cells (Juliano and Ling, 1976). Since then, it 
has been shown that around 60% of all anticancer drugs are effluxed out by ABCB1, 
in turn, reducing the amount of drug accumulation in the tumor cells (van Tellingen et 
al., 2015). Accordingly, ABCB1 heavily impacts the brain penetration of several 
anticancer agents (Demeule et al., 2002).  
The BBB also strictly regulates the access of immune cells to the brain. This tight 
regulation, along with the lack of a classical lymphatic system, and the observation that 
cells in the brain express low levels of the major histocompatibility complexes (MHC) 
proteins, led to the assumption that the CNS is an immunoprivileged site (Lampson 
and Hickey, 1986). Nonetheless, although at steady state, only few immune cells are 




inflammatory stimuli render the BBB more permeable, which in turn, allows the brain 
trafficking of immune cells (Hickey et al., 1991; Claudio, 1996; Lou et al., 1997).   
Several lines of evidence have demonstrated that antigens released in the CNS are 
drained into the peripheral cervical lymph nodes, where they can be taken up by 
professional antigen-presenting cells (APC) and be presented to naïve T cells. Only 
when activated in the cervical lymph nodes, T cells can up-regulate the specific 
expression of α4 and β1 integrins. These integrins allow for the passage of activated 
T cells through the BBB via specific interaction with vascular cell adhesion molecule 
(VCAM)-1 expressed on the surface of the brain endothelium (Calzascia et al., 2005; 
Dunn et al., 2012).  
In the brain cancer context, it has been long assumed that most of the cancer immune-
surveillance happens in the meningeal compartment. However, recent studies have 
shed new light on this matter and changed the view of the immune cell trafficking in 
and out of the brain. Studies performed independently by two laboratories showed the 
existence of a dural lymphatic vascular system, which drains fluids, macromolecules 
and immune cells from the cerebrospinal fluid, and is ultimately connected to the 
cervical lymph nodes in animal models (Aspelund et al., 2015; Louveau et al., 2015) 
(Figure 5). Although functional experiments are still required to fully assess the 
importance of immune cell trafficking during physiological and pathological conditions 
along the dural lymphatic system, this discovery shifts a long-held paradigm on CNS 





Figure 5. Newly discovered dural lymphatic system. A. Lymphatic vessel endothelial hyaluronan 
receptor 1 (LYVE-1) staining of whole-meninges section shows the existence of lymphatic vessels 
adjacent to the dural sinuses. B. Schematic graphic representation of dural lymphatic vessels 
position within the brain architecture. 




To a variable extent, immune cell infiltration within the brain tumor parenchyma has 
been found (Masson et al., 2007; Donson et al., 2012; Han et al., 2014). During tumor 
development, the BBB can be partially disrupted, becoming more permeable to 
immune cell entry and administered drugs. Yet, intact zones of the BBB can protect 
tumor cells invading the brain parenchyma from anticancer agent delivery (Figure 6). 
This represents a major therapeutic problem and may likely be a possible explanation 
for the disappointing results achieved by targeted therapies against glioblastoma 
(Agarwal et al., 2013; Olson et al., 2014; Becker et al., 2015). Many efforts are currently 
ongoing to thwart BBB drug-extrusion activity, which in turn, may improve the efficacy 





Figure 6. Blood brain barrier (BBB) integrity and composition in glioblastoma. During 
glioblastoma progression, the BBB possesses a heterogeneous structure: In the left panel, barrier 
integrity is completely compromised. The middle panel illustrates few zones of leakiness and the 
presence of some glioblastoma-infiltrating cells. Lastly, in the right panel, the BBB is intact and single 
invasive tumor cells may be present. Importantly, while disrupted zones of the BBB allow small 
molecules and antibodies penetrance within the tumor, intact zones may protect tumor cells 
infiltrated in the brain parenchyma distant from the primary tumor. These cells cannot be resected 
via surgical procedures and most likely are responsible for tumor recurrence and resistance to 





3.4.2 Immunosuppressive immune cell subsets 
 
3.4.2.1 Regulatory T cells 
Around 5-10% of all circulating CD4+ T cells are regulatory T cells (Treg). This T cell 
subset is a key modulator of immune system’s activity playing a central role in 
controlling tolerance to self and host antigens and impeding outbreak of autoimmune 
processes by resolution of inflammation (Sakaguchi, 2004). Treg display specific 
markers that distinguish these cells from other T cell subsets. Specifically, Treg are 
defined by interleukin-2 receptor alpha chain (also known as CD25), glucocorticoid-
induced tumor necrosis factor receptor (GITR), and cytotoxic T lymphocyte antigen 
(CTLA)-4 expression (Wainwright et al., 2013). Moreover, Treg can be further 
subdivided into two functional classes: natural Treg (nTreg) that developed in the 
thymus, and induced Treg (iTreg), which emerge from conventional T cells that start 
to express forkhead box P3 (FoxP3) in an immunosuppressive micro-milieu. In 
glioblastoma patients, Treg percentages are increased in the peripheral blood and 
tumor biopsies and this is associated with higher tumor grade and worse prognosis 
(Fecci et al., 2006; El Andaloussi and Lesniak, 2007; Heimberger et al., 2008). Other 
studies suggest that the presence of Treg in the blood or tumor is not a negative 
prognostic factor (Lohr et al., 2011; Han et al., 2014; Thomas et al., 2015). 
Contradictory data may be due to the existence of different Treg subsets, which can 
be distinguished only through multi-marker panels and not only via FoxP3 detection. 
In murine models, infiltrating Treg within gliomas are mainly thymus-derived nTreg. 
The recruitment of these cells was significantly impaired in mice previously 
thymectomized (Wainwright et al., 2011). These data suggest that glioma cells can 
readily recruit nTreg from the periphery, principally through the 
chemokine/chemoreceptor pathway C-C motif chemokine ligand (CCL)22/C-C motif 
chemokine receptor (CCR)4 (Jacobs et al., 2010). In a spontaneous astrocytoma 
model, Thang and colleagues demonstrated that at pre-symptomatic tumor stages, 
there was a significant infflux of CD4+ and CD8+ cells, with a significant fraction being 
CD4+ CD25+ T cells which include Treg (Thang et al., 2010). The importance of this 
cell subset in disrupting anti-tumor immunity has been shown in several pre-clinical 
models. In the syngeneic SMA-560 orthotopic VM/Dk model, treatment with a 
monoclonal antibody against CD25 led to functional inactivation of Treg and restored 




resulted in heightened anti-glioma immunity, partly via diminished intratumoral Treg 
infiltration most probably due to impaired trafficking from the periphery (Ueda et al., 
2009). Treg blockade has also been translated in clinical settings and daclizumab, a 
humanized monoclonal antibody against CD25, has shown promising preliminary data 
in glioblastoma patients (Sampson et al., 2012). More recently, Treg have been 
attributed with new intriguing roles. Lowther and colleagues have detected a 
dysfunctional Treg cell population, which displays high expression of programmed cell 
death 1 (PD-1) and has weak suppressive activity and produces IFN-γ (Lowther et al., 
2016). Also, in accordance with the role of Treg in resolving inflammatory states, these 
cells can induce tissue repair by secreting the EGF family ligand amphiregulin (Arpaia 
et al., 2015; Leavy, 2015). These new findings highlight a wider role played by these 
cells during physiological and pathological conditions, and possibly challenge the view 
of an exclusive inhibitory effect on antitumor immunity.  
 
3.4.2.2 Glioma-associated microglia/macrophages and myeloid-derived 
suppressor cells 
Microglia and macrophages represent the most prominent immune infiltrate in 
glioblastoma and great attention has been posed on their role in tumor development 
and progression (Morantz et al., 1979; Morimura et al., 1990). These cells can build up 
to 12% of the tumor mass and their presence correlates with higher tumor grade 
(Nishie et al., 1999; Badie and Schartner, 2000). Importantly, infiltrated 
microglia/macrophages are re-programmed to support tumor growth and resistance to 
therapeutic intervention. Experimentally, microglia and macrophages have been 
defined by differential expression of the CD45 surface marker. Microglia cells have 
been distinguished as CD45low whereas macrophages are CD45high. However, during 
inflammatory states, microglia can upregulate CD45 expression making distinctions 
between these two population challenging (Parney et al., 2009; Muller et al., 2015). To 
date, it is still not possible to clearly separate these two populations as they are 
characterized by a wide phenotypic plasticity. Nonetheless, from the functional 
perspective, these populations have been divided in two phenotypic classes: the 
classically activated M1 and the alternatively activated M2 state. M1-polarized 
microglia/macrophages have a pronounced anti-tumor activity and produce high 
amounts of pro-inflammatory cytokines, whereas M2 skewed cells tune down 




et al., 2002). Importantly, these two functional polarizations are rather extremes of a 
wide phenotypic continuum. 
In glioblastoma, tumor-associated macrophages show a M2 immunosuppressive 
phenotype and secrete a plethora of pro-tumorigenic molecules such as TGF-β, VEGF, 
EGF and MMP-2, which drive various oncogenic features (Platten et al., 2001; 
Markovic et al., 2005; Komohara et al., 2008; Wesolowska et al., 2008; Coniglio et al., 
2012; Riabov et al., 2014). Targeting of colony stimulating factor-1 receptor (CSF-1R), 
a key receptor that promotes macrophage differentiation, survival, and pro-tumorigenic 
functions, significantly increased the survival of glioma-bearing mice by the re-
polarization of microglia/macrophages to an anti-tumor M1 phenotype (Pyonteck et al., 
2013).  
Myeloid-derived suppressor cells (MDSC) are another important immunosuppressive 
cell subset in glioblastoma. In mice, MDSC are usually referred to as CD11b+ Gr-1int 
Ly6C+ and comprise immature cells containing common precursors of both monocytic 
and granulocytic lineages (Peranzoni et al., 2010). This immature cell subset is 
recruited by tumors from the bone marrow and directly inhibits cytotoxic T cells through 
nitric oxide (NO) release in a rat glioma model (Jia et al., 2010). Hypoxia is a main 
driver for MDSC recruitment and its presence is linked to decreased number of tumor-
infiltrating T cells in human and murine gliomas (Corzo et al., 2010; Raychaudhuri et 
al., 2015). Interestingly, hypoxia-driven HIF-1α up-regulates PD-ligand 1 (PD-L1) 
expression in glioma-infiltrating MDSC. This finding links the cellular 
immunosuppressive function of MDSC to the PD-1 pathway (for details see section 
3.6.1 and 3.6.2) (Noman et al., 2014). Importantly, despite their prominent role in 
tumor-associated immunosuppression, the existence of some MDSC subsets remains 
controversial and requires further investigation (Marvel and Gabrilovich, 2015).  
In conclusion, tumor-associated microglia/macrophages and MDSC have many 
overlapping inhibitory functions and possess an intrinsic high phenotypic plasticity.  
 
3.4.3 Glioma-derived soluble immunosuppressive factors 
Glioma cells can secrete a variety of soluble molecules, which contribute to the harsh 
immune-inhibitory microenvironment (Figure 7). Among the most prominent 
immunosuppressive factors are TGF-β family ligands, which are thoroughly discussed 




VEGF it is not only involved in glioma angiogenesis. Indeed, it can dampen APC 
maturation and function, and can induce the expression of PD-1 and CTLA-4 on the 
surface of CD8+ T cells, impairing their antitumor activity (Gabrilovich et al., 1996; 
Voron et al., 2015). Glioma cells can also produce IL-10, which can induce PD-L1 
expression on monocytes and regeneration and tolerance factor (RTF) that can shield 
glioblastoma cells from natural killer cell attack (Roth et al., 2006; Bloch et al., 2013). 
Other immunosuppressive secreted molecules are arginase I, NO and prostaglandin 
E (PGE)-2. Arginase I presence in the sera of glioblastoma patients is strongly 
associated with general immunosuppression and NO and PGE-2 can be secreted by 
adult neural stem/progenitor cells suppressing T cell effector functions (Wang et al., 








Figure 7. Soluble immunosuppressive factors secreted by glioma cells. Glioma cells employ 
various soluble factors to generate an immunosuppressive microenvironment. TGF-β impairs T cell 
cytotoxic functions by inhibiting IFN-γ, granzyme B (GZMB) and NKG2D, shifts macrophages 
polarization toward an M2 tumor-promoting phenotype, and stimulates Treg induction and 
recruitment to the tumor. VEGF hinders efficient antigen presentation, and rise the expression of 
immune checkpoint receptors on CD8+ effector cells. IL-10, RTF, colony stimulating factor (CSF)-1, 
arginase (Arg) I, NO, andPGE2 altogether contribute to glioma cell-induced immunosuppression. 




3.5 TGF-β superfamily 
The TGF-β superfamily comprises around 30 members. TGF-β ligands, bone 
morphogenetic proteins (BMP), activins, nodal, growth and differentiation factors 
(GDF), and anti-Müllerian hormone (AMH) are all superfamily members and play 
fundamental roles in various processes spanning from the early developmental stages 
to tissue maintenance and homeostasis in adult mammals (Wakefield and Hill, 2013).  
 
3.5.1 TGF-β pathway 
In mammals three main TGF-β ligand isoforms exist: TGF-β1, TGF-β2, and TGF-β3. All 
the ligands of the family are produced as precursors and are activated by pro-protein 
convertase mediated-cleavage (Akhurst and Hata, 2012). Activated ligands can homo- 
or heterodimerize through disulphide bonds and can initiate a transduction cascade 
via membrane receptors. Usually, two main types of serine/threonine membrane 
receptors are required: a type I and a constitutively active type II receptor. Upon ligand 
binding, the constitutive active type II trans-phosphorylates the type I, which then 
recruits SMAD proteins initiating the signal transduction to the nucleus (Figure 8). TGF-
β ligands can also commence a non-canonical signalling via activation of several 
intracellular mediators such as the RAS pathway, PI3K, TGF-β-activated kinase (TAK)-
1 and nuclear factor kappa B (NF-Κb), which all together can generate the pleiotropic 
responses mediated by this pathway (Akhurst and Hata, 2012) (Figure 9). Of note, 
signalling activity and strength can be further modulated by the co-receptors endoglin 
and betaglycan, adding another layer of complexity (Bernabeu et al., 2009). 
Knockout mice for TGF-β1 are embryonic lethal due to vascular defects (Dickson et al., 
1995). TGF-β2 null mice possess multiple developmental defects, which do not 
recapitulate the TGF-β1 or TGF-β3 knockout mice phenotype suggesting that these 
ligands have also non-overlapping functions (Sanford et al., 1997). In humans, 
mutation of the TGFβRI activing receptor-like kinase (ALK)-1 or of the co-receptor 
endoglin cause an autosomal dominant disorder termed Hereditary Haemorrhagic 
Teleangiectasia (HHT), which is characterized by vascular dysplasia (McAllister et al., 




























Figure 8. Canonical TGF-β pathway. TGF-β is activated by pro-protein convertase cleavage and 
can dimerize and thereafter bind its receptors. Upon binding, type II and type I receptors 
heterodimerize and recruit SMAD2 or SMAD3, which are phosphorylated and bind the common 
mediator SMAD4. The formed complex can translocate into the nucleus where it can either induce 
or repress target genes expression. SMAD complexes can also influence the biogenesis of 
microRNA. SMAD7, and the nuclear proteins SKI and SNO, are negative regulators of the pathway. 









3.5.2 The TGF-β pathway in glioblastoma 
TGF-β is a multifunctional cytokine implicated in several physiological processes in a 
cell-specific and context-dependent manner. Despite the fact that TGF-β initially 
functions as a “barrier” against cancer development, a strong correlation between this 
molecule and the level of malignancy, as well as poor prognosis has been 
demonstrated in glioma in some studies, although this has not been confirmed in our 
laboratory (Bruna et al., 2007; Massague, 2008; Hau et al., 2011; Frei et al., 2015).  
TGF-β2 was initially discovered as glioblastoma derived T cell suppressor factor (GsT) 
due to its ability to disrupt IL-2-mediated T cell survival (Schwyzer and Fontana, 1985). 
Since then, many other immunosuppressive and tumor-promoting functions have been 
Figure 9. Non-canonical TGF-β pathway. 
TGF-β signalling can activate multiple downstream pathways. Besides the classical SMAD-mediated 
signalling, TGFβR can signal through the RAS/MAPK pathway, TAK1, p38 mitogen-activated protein 
kinase (p38),  PI3K/AKT pathway, RHO/ROCK axis, tumor necrosis factor receptor associated factor 
(TRAF)-4 and -6, and NF-κB. All these pathways are activated in a context-specific cell-dependent 
manner, and regulate most of the pleiotropic TGF-β-induced responses. 





attributed to TGF-β. All three isoforms are expressed in glioblastoma, yet, while TGF-
β1 and TGF-β2 have been attributed clear roles in repressing immune functions within 
the tumor microenvironment, fewer data have been collected for TGF-β3 (Pickup et al., 
2013; Frei et al., 2015; Seystahl et al., 2017). When exposed to TGF-β, CD4+ T cells 
can differentiate into Treg by up-regulating the lineage-defining nuclear transcription 
factor FoxP3 (Chen et al., 2003; Fu et al., 2004). Moreover, the function of CD8+ 
cytotoxic T cells are greatly suppressed by TGF-β via activation of a repressive 
transcriptional circuit. Indeed, a complex formed by SMAD/ATF1 proteins can inhibit 
the expression of IFN-γ and granzyme B, which are required to carry out T cell-
mediated anti-tumor responses (Thomas and Massague, 2005). Also, TGF-β activity 
can shield tumor cells from an immune attack by down-modulating the expression of 
NKG2D, an activating receptor for NK cells and co-stimulatory molecule for CD8+ cells, 
and by reducing the expression of the NKG2D ligands MICA and ULBP2 on the cell 
surface of glioma cells (Friese et al., 2004; Eisele et al., 2006). Other immune-
repressing activities orchestrated by TGF-β include polarization of myeloid cells toward 
a pro-tumorigenic phenotype and diminished antigen presentation by dendritic cells 
(DC) (Fridlender and Albelda, 2012; Gong et al., 2012). Of note, other members of the 
TGF-β superfamily such as GDF-15 may also suppress immune effector mechanisms 
(Roth et al., 2010). 
Pleiotropic activity of the TGF-β pathway encompasses multiple pro-tumorigenic 
features, far beyond immunosuppression. TGF-β activity may be crucial for 
tumorigenicity, self-renewal, survival, and resistance of GSC to radiotherapy (Ikushima 
et al., 2009; Penuelas et al., 2009; Anido et al., 2010; Hardee et al., 2012). Also, TGF-
β fosters the malignant phenotype of glioblastoma  through induction of angiogenesis, 
proliferation, migration, and invasion (Platten et al., 2001; Wick et al., 2001; Ishihara 
et al., 2008; Dieterich et al., 2012; Krishnan et al., 2015).  
Due to its extensive role in the malignant phenotype of glioblastoma, TGF-β has been 
regarded as a promising molecular target. Although TGF-β inhibition has proven 
remarkable efficacy in various preclinical glioma models, translation of these results 
into the clinic has been disappointing (Uhl et al., 2004; Ueda et al., 2009). A phase II 
trial in recurrent glioblastoma with the TGFβRI inhibitor galunisertib was ineffective to 
prolong progression-free or overall survival (Brandes et al., 2016). However, TGF-β 
inhibition is still of interest, especially, in combinatorial approaches targeting different 









Lafferty and Cunningham proposed the widely accepted model of naïve T cell 
activation in 1975 (Lafferty and Cunningham, 1975). This model postulates that T cells 
require a double positive signal in order to become fully activated. The first signal is 
highly specific and dictated by the interaction between a peptide loaded on a MHC-
complex with the T cell receptor (TCR). The second stimulus, also called costimulatory 
signal, is antigen-independent and is delivered by APC to induce all the characteristic 
features possessed by activated T cells such as clonal expansion or cytokine 
secretion. Without the second signal, T cells cannot respond to antigen stimulation and 
rather become anergic and subsequently even tolerant to that antigen. The classical 
costimulatory signal happens when CD80 or CD86 present on the mature APC 
membrane bind to CD28 found on T cells, delivering the second signal and inducing 
full T cell activation (Pardoll, 2012). Costimulatory molecules that deliver negative 
signals also exist and are referred as to immune checkpoints. These molecules are 
regulators of T cell activation, are critical for preserving self-tolerance, and modulate 
Figure 10. CTLA-4 and PD-1 immune checkpoint pathways. 
A. CTLA-4 acts at the initial stages of the immune response. It is induced in an amplitude-dependent 
manner during T cell activation, and competes with the CD80/CD86 costimulatory molecules for 
CD28 binding, dampening T cell responses. B. The PD-1 pathway regulates inflammatory T cell 
responses in peripheral tissues. Activated T cells start to express increasing levels of PD-1 in time, 
while inflammatory signals induce the expression of PD-L1 and PD-L2 in tissues. When PD-1 
engages its ligand expressed by cells present within the inflamed tissue, T cells receive a negative 
signal that dampens their effector activity. 





duration and magnitude of immunological responses. To date, two major checkpoints 
have been regarded as the most relevant for cancer immunotherapy: CTLA-4 and PD-
1 (Figure 10).  
CTLA-4 acts in the initial steps of T cell activation and its inhibitory function depends 
on the magnitude of the initial response; MHC-peptide complexes with high affinity for 
the TCR produce higher induction of CTLA-4 expression. This mechanism allows the 
maintenance of a fine balance between positive and negative signals and permits a 
constant T cell activation that is less dependent from antigen concentration and ligand 
affinity (Pardoll, 2012). Differently from CTLA-4, PD-1 acts after the initial step to 
regulate T cell activation in peripheral tissues, limiting inflammation-related collateral 
damages.     
 
3.6.1 PD-1 pathway 
In 1992, Ishida and colleagues discovered the PD-1 receptor as a molecule that was 
up-regulated in a T cell hybridoma cell line during apoptosis (Ishida et al., 1992). The 
first compelling evidence of the role of PD-1 in immune regulation comes from the 
phenotype displayed by Pdcd1-null mice, which are prone to develop different 
autoimmune diseases in a strain-dependent manner (Nishimura et al., 1999; Nishimura 
et al., 2001). The phenotypes exhibited by PD-1 knockout mice show the role of this 
receptor in controlling the induction and maintenance of T cell tolerance, thus acting 
mainly as an immunological rheostat and highlight the differences with CTLA-4 null 
mice, which die from fatal multi-organ failure caused by uncontrolled 
lymphoproliferation (Tivol et al., 1995; Waterhouse et al., 1995).  
Upon binding to one of its ligands, PD-L1 or PD-L2, PD-1 is phosphorylated in its 
intracellular tail and recruits the SH2-domain containing tyrosine phosphatase (SHP)-
2 protein, which in turn, hinders TCR signalling and subsequent T cell activation 
(Sheppard et al., 2004). Mechanistically, PD-1 activation leads to inhibition of the anti-
apoptotic protein B cell lymphoma-extra large (Bcl-xL) and reduced expression of 
transcription factors implicated in T cell effector mechanisms such as GATA-3, Tbet 
and Eomes (Chemnitz et al., 2004; Nurieva et al., 2006). 
PD-L1 is present on almost all human and mouse cells and its constitutive and 
inducible expression is regulated by interferon signalling, since two IFN regulatory 




al., 2008). Differently, PD-L2 expression is rather restricted to few hematopoietic cells, 
such as DC and macrophages, and mainly inducible by inflammatory stimuli.  
PD-1 ligands can also have different binding partners. Recently, it has been shown 
that PD-L1 can also bind CD80 with higher affinity than CD28, but lower than CTLA-4. 
Interestingly, PD-L1 can be found on the surface of T cells and knockout studies have 
shown that signalling through this ligand exert an additional inhibitory signal (Latchman 
et al., 2004).  
Although PD-L2 cannot bind CD80, another binding partner has been identified. 
Repulsive guidance molecule b (RGMb), a coreceptor for BMP signalling, can bind PD-
L2 and this engagement is fundamental in promoting respiratory tolerance, adding an 
ulterior layer of complexity to this pathway (Xiao et al., 2014).  
 
3.6.2 The PD-1 pathway in glioblastoma 
Given that PD-1 transduces an inhibitory signal to the activated T cell, PD-L1-
expressing tumor cells can protect themselves from an immune attack by a mechanism 
called “molecular shield” (Azuma et al., 2008). The relevance of this pathway lies in 
the observation of so far unseen clinical responses achieved by PD-1 blockade in 
hitherto unresponsive tumors such as advanced metastatic melanoma and non-small 
cell lung cancer (Wolchok et al., 2013; Rizvi et al., 2015). Efficacy of PD-1 targeting 
agents are yet to be determined in glioblastoma, however, they are being currently 
evaluated in both newly diagnosed and recurrent glioblastoma (Preusser et al., 2015; 
Weiss et al., 2015).  
Various preclinical studies in vitro and in vivo have confirmed PD-L1 expression in 
glioma cells (Wintterle et al., 2003; Wilmotte et al., 2005; Jacobs et al., 2009; Berghoff 
et al., 2015; Nduom et al., 2016). At the molecular level, PD-L1 expression in 
glioblastoma has been linked with PTEN loss and NF1 mutation with subsequent 
MAPK pathway activation (Parsa et al., 2007; Heiland et al., 2017). Conversely, no 
evidence so far has been provided for PD-L2 expression in glioblastoma. Importantly, 
PD-L1 levels are dramatically enhanced by IFN-γ stimulation. This mechanism, called 
adaptive resistance, has a crucial role during inflammatory response as it protects 
normal tissues from collateral damages that can be caused by uncontrolled T cell 
activation. Tumors can efficiently hijack this process shielding themselves from 
immune recognition and elimination (Tumeh et al., 2014). Therapeutic efficacy by PD-




preclinical glioma models. Best results were achieved when PD-1 inhibition was 
administered in combination with radiotherapy or other checkpoint inhibitors (Zeng et 
al., 2013; Wainwright et al., 2014; Reardon et al., 2016). As already mentioned, PD-L1 
is ubiquitously expressed and induced by inflammatory stimuli. As a consequence all 
cell types residing in the tumor micro-milieu can provide negative signals to infiltrated 
T lymphocytes. Gliomas can mediate an IL-10-dependent paracrine loop that induces 
PD-L1 expression in tumor-associated macrophages, which results in heightened 
immunosuppression (Bloch et al., 2013). In another study, an IFN-β-mediated 
autocrine loop in human neurons enhances PD-L1 expression and this was linked with 
induction of apoptosis in glioma cells and improved survival of glioma patients (Liu et 
al., 2013). Accordingly, a recent paper has shown that PD-L1 from different cell type 
sources within the tumor microenvironment can non-redundantly contribute to 
immunosuppression (Lau et al., 2017).  
Intriguingly, several reports have shown that the role of PD-L1 may extend beyond 
immunosuppression. In fact, this ligand provides reverse signalling into the cell, which 
may provide anti-apoptotic stimuli to the tumor cell (Azuma et al., 2008). Moreover, 
membrane-bound PD-L1 can increase tumor cell glycolytic activity, thereby sustaining 
tumor cell immune escape by withdrawing glucose bioavailability from T cells, which 
highly depend on this molecule to efficiently activate their effector phenotype (Chang 
et al., 2015). Mechanisms by which PD-L1 regulates tumor cell metabolism are poorly 
understood and have never been investigated in glioblastoma warranting further 
investigation. In conclusion, these studies highlight that the PD-1/PD-L1 pathway may 
represent a key tumor-promoting hub, which plays a dual role in protecting tumor cells 














4. Materials and Methods 
 
Reagents 
Recombinant human TGF-β2 was purchased from R&D systems (Minneapolis, MN), 
murine VEGF (VEGF120) from biolegend (San Diego, CA) and murine IFN-γ from 
peprotech (Rocky Hill, NJ). B20 was kindly provided by T. R. Schwartz (Genentech, 
South San Francisco, CA), cediranib by AstraZeneca (London, UK), LY2157299 (LY) 
by Eli Lilly & Co. (Indianapolis, MN), SD-208  by Scios Inc. (Freemont, CA) and anti-
PD-1 (78AFS) by Merck (Boston, MA). 
 
Cell lines 
Murine SMA-497, SMA-540 and SMA-560 glioma cells were kindly provided by D.D. 
Bigner (Durham, NC). GL-261 cells were received from the National Cancer Institute 
(Frederick, MD). The cells have been characterized extensively in our laboratory 
(Ahmad et al., 2014) and are commonly cultured as adherent monolayers in 
Dulbecco`s modified Eagle medium (DMEM) (Gibco, Invitrogen AG, Basel, 
Switzerland) supplemented with 10% heat-inactivated fetal calf serum (FCS) 
(Biochrom KG, Zug, Switzerland) and 2 mM glutamine (Biochrom KG) (DM medium). 
Hypoxia treatment was done in a hypoxia chamber 1% O2 atmosphere at 37°C. 
 
Viability and clonogenicity assays 
Viability was assessed after pooling adherent and floating cells by trypan blue dye 
exclusion. Clonogenicity was assessed as previously described (Happold et al., 2014). 
Briefly, 100 cells per well were seeded in 96-well or 6-well plates, allowed to adhere 
overnight, and treated for 24 h with either LY2157299 (Eli Lilly & Co, 1 µm), cediranib 
(AstraZeneca, 100 nM), or B20 (Genentech, 100 µg/ml) in fresh medium followed by 
an observation period for 10 to 14 days in serum-containing medium. Cell density was 
assessed by counting crystal violet stained cultures.  
 
Real-time PCR (RT-PCR) 
Total mRNA for baseline gene expression analyses was extracted from murine glioma 
cells or from in vivo tumor tissue (Seystahl et al., 2015). For RT-PCR, gene expression 
was measured using the Real Time PCR System 7300 (Applied Biosystems, Foster 




at optimized concentrations. The conditions for RT-PCR were 40 cycles, 95°C/15s, 
60°C/30s, 72°C/30s. Relative quantification of gene expression was determined by 
comparison of cycle threshold values. Hypoxanthine phosphoribosyltransferase 1 
(HPRT1) was used as a housekeeping gene and specific target gene expression was 
normalized to HPRT1 and calculated with the ΔCT-method for relative quantification 
with respect to primer efficiency calculated by the standard curve method. The 
following mouse-specific primers were used: HPRT1 (forward 5'-
TTGCTGACCTGCTGGATTAC-3', reverse 5'-TTTATGTCCCCCGTTGACTG-3'), 
VEGF (forward 5'-CACGACAGAAGGAGAGCAGA-3', reverse 5'-
GGGCTTCATCGTTACAGCAG-3’), VEGFR1 (forward 5'-
AGAGGAGGATGAGGGTGTCT-3’, reverse 5’-GGGAACTTCATCTGGGTCCA-
3’),VEGFR2 (forward 5’-GCTCCTGACTACACTACCCC-3’, reverse 5’- 
AGGAAACAGGTGAGGTAGGC-3’), TGF-β1 (forward 5′-
TGGAGCAACATGTGGAACTC-3′, reverse 5′- GTCAGCAGCCGGTTACCA-3′), TGF-
β2, (forward 5′-GCCCACTTTCTACAGACCCT -3′, reverse 5′- 
CCTTGCTATCGATGTAGCGC-3′), ALK-5 (forward 5’- 
TGGGACTTGCTGTGAGACAT-3’, reverse 5’- CCACCAATAGAACAGCGTCG-3’) and 
TGF-βR2 (forward 5’-CTGTTGCCTGTGTGACTTCG-3’, reverse 5’-
AACGACTCCACGTTTTC-3’), PD-L1 (forward 5’-CTCCTCGCCTGCAGATAGTT-3’, 
reverse 5’-ATCGTGACGTTGCTGCCATA-3’), PD-L2 (forward 5’- 
GTGCTGGGTGCTGATATTGAC-3’, reverse 5’-AAAATCGCACTCCAGGCTCA-3’) 
(all Microsynth, Balgach, Switzerland). 
 
Immunoblot analyses 
For immunoblot analysis, whole cell lysates were prepared using RIPA lysis buffer 
containing 1% NP-40, 0.5% sodium deoxycholate, 50 mM Tris/HCl pH 8.0, 150 mM 
NaCl, 5 mM EDTA pH 8.0, 0.1% SDS in Milli-Q water supplemented with 2 µg/mL 
aprotinin, 10 µg/mL leupeptin, 100 µg/mL phenylmethylsulfonyl fluoride (Sigma Aldrich, 
St. Louis, MO), phosphatase inhibitor cocktails 2 and 3 (Sigma Aldrich). Protein levels 
were determined using BCA Protein Assay Kit (Pierce/Thermo Fisher, Madison, WI). 
After SDS-PAGE (8 – 12 % acrylamide gels, Biorad, Hercules, CA) under reducing 
conditions with loading of equal amounts of proteins, proteins were transferred to 
nitrocellulose membranes (Biorad), blocked in Tris-buffered saline containing 5% skim 




recommended by the manufacturers: anti-VEGFR1 (R&D Systems, AF471, 1:500), 
anti-VEGFR2 (Cell Signaling, Leiden, Netherlands, #2479, 1:500), anti-pSMAD2 (Cell 
Signaling, #3108, 1:1000), anti-ALK-5 (Santa Cruz Biotechnology, Inc., Dallas, TX, sc-
9048, 1:500), anti-TGFβR2 (R&D Systems, AF532, 1:500), anti-β-actin (Santa Cruz 
Biotechnology, Inc., sc-1616, 1:2000). Visualization of protein bands was 
accomplished using horseradish peroxidase (HRP)-coupled secondary antibodies 
(Santa Cruz) and enhanced chemoluminescence (Pierce/Thermo Fisher, Madison, 
WI). For quantitative correlation analyses of baseline expression of total and 
phosphorylated proteins, band intensity was analyzed via densitometry using ImageJ 
software (http://imagej.nih.gov/ij/index.html, Open Source).  
 
Enzyme-linked immunosorbent assay (ELISA) 
Supernatants were collected from subconfluent glioma cell cultures after the indicated 
time periods. Treatments were performed in serum-free medium for the indicated time 
periods. Cellular debris was removed by centrifugation and supernatants were 
concentrated using 3K-Amicon® Ultra-4 Centrifugal Filter Units (Millipore AG, Zug, 
Switzerland). ELISA kits for murine VEGF (VEGF, eBiosciences, San Diego, 
BM5619/2), murine TGF-β1 (eBiosciences, BMS608/4) and TGF-β2 (R&D, MB200) 
were used. Results were normalized to the cell numbers at the time of harvesting. 
 
Animal studies 
The standard operating procedures for the animal studies were approved by the Swiss 
Cantonal Veterinary Office under the Animal license permission number 38/2012 and 
132/2011. The care and treatment of all animals was in accordance with the Swiss 
Federal Law on the Protection of Animals, the Swiss Federal Ordinance on the 
Protection of Animals and the guidelines of the Swiss confederation. Following 
anesthesia, a burr hole was drilled in the skull 1.5 mm lateral and 1 mm posterior to 
the bregma. The needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was 
introduced to a depth of 3 mm. A volume of 2 μl of a single cell suspension in PBS was 
slowly injected into the right striatum. In VM/Dk mice 5 x 103 SMA glioma cells were 
implanted, whereas in C57Bl/6 mice 2 x 104 GL-261 cells were implanted (n=10 per 
group). For project 1 systemic treatment was performed by i.p. injections of B20 (5 
mg/kg body weight twice weekly) or the solvent PBS, or by oral gavage delivering the 




HEC/0.25% v/v Tween 80/ 0.05 v/v Antifoam 1510-US in H2O).The mice were 
observed daily and euthanized when developing neurological symptoms or at defined 
time points for histological analysis as indicated. Three mice per group were commonly 
euthanized using pre-randomization when any mouse in the experiment became 
symptomatic in order to perform histological studies to assess tumor growth at an early 
stage. The remaining 7 mice were euthanized when displaying neurological symptoms 
to obtain survival or histological data (end-stage). Where indicated, mice brains were 
explanted for snap-frozen samples. All brains were collected upon euthanization, 
embedded in cryomoulds in Shandon Cytochrome yellow (Thermo Scientific, Waltham, 
MA) and frozen in liquid nitrogen. Tumor incidences and sizes were determined using 
hematoxylin and eosin stainings of 8 µm thick cryosections using a Microm HM560 
(Microchom HM560, Thermo Scientific). 
 
Immunohistochemical analysis 
Cryosections were fixed in 4% formalin, acetone or methanol/acetone for 10 min, air-
dried, pretreated with 0.3-3% H2O2 and blocked in 10% rabbit or donkey serum or 
blocking solution (Candor Biosciences, Wangen, Germany). After blocking, the primary 
antibodies were applied for 1 h at 37°C or overnight at 4°C. Primary antibodies were 
polyclonal goat anti-CA IX (R&D Systems, AF2344, 1:50), monoclonal rat anti-CD4 
(BD Pharmingen, 553727, 1:100), monoclonal rat anti-CD8a (BD Pharmingen, 
BD550281, 1:50), polyclonal rabbit anti-CD11b (Abcam, Cambridge, UK, ab75476, 
1:400), monoclonal rat anti-CD31 (BD Pharmingen, Allschwil, Switzerland, BD550274, 
1:50), monoclonal rat anti-CD45 (Biolegend, San Diego, CA, 103102, 1:1000), 
monoclonal rabbit anti-Ki-67 (Epitomics, Burlingame, CA) and monoclonal rabbit anti-
pSMAD2 (Cell Signaling, 3108, 1:1000). Biotinylated secondary antibodies, 
streptavidin and 3,3′-diaminobenzidine (DAB) were obtained from Dako (Baar, 
Switzerland). Histofine Simple Stain Mouse MAX PO secondary-labelled antibody 
system was obtained from Nichirei (Tokyo, Japan). Secondary antibodies were 
incubated for 30 min at room temperature. The antigen antibody conjugates were then 
detected by staining with DAB (Dako) for 1-3 min. The nuclei were stained using 
hematoxylin for up to 4 min, washed in water and dehydrated twice in 96% ethanol, 
then twice in 100% ethanol and three times in xylol before mounting onto coverslips 
using Eukitt mounting medium (Sigma Aldrich). Quantification of immunohistological 




tumor tissue, percentages of CD11b- and CD45-positive cells of all nucleated cells 
were determined, microvessel density (MVD) was calculated by counting CD31+ 
capillaries, and infiltrating CD4 and CD8a positive cells per ROI were counted. 
Quantification of pSMAD2-positive cells was performed by H scoring in four randomly 
selected, different microscopic fields of independent hotspots (tumor margin) and 
tumor centers on the basis of both the percentage of positive tumor nuclei and staining 
intensity in tumors (Frei et al., 2015). In brief, to obtain scores, staining intensity is 
scored as absent (0), mild (1), moderate (2) or strong (3) expression. The staining 
intensity value is multiplied by the percentage of cells showing each grade of positivity, 
thus, the maximum H score is 300 (Kinsel et al., 1989; Kraus et al., 2012). The surface 
detection function within the Image J software was used for the quantification of 
CD11b-, CD45- and Ki-67-positive cells and for carbonic anhydrase (CA) IX-positive 
areas. Tumor volumes were calculated using an approximation based on ellipsoid 
geometric primitive (Schmidt et al., 2004).  
 
Immunofluorescence microscopy 
Immunofluorescence studies were carried out on cryosections of tumor-bearing mouse 
brains. The following antibodies were applied overnight at 4°C: polyclonal anti-CA IX 
(R&D Systems, 1:50), monoclonal anti-CD31 (BD Pharmingen, 1:50), monoclonal 
pSMAD2 (Cell Signaling, 1:500), monoclonal rat anti-VEGFR1 (Biolegend, 136402, 
1:50) and monoclonal rabbit anti-VEGFR2 (Cell Signaling, 2479, 1:200). Binding 
specificity was controlled by IgG isotype control (Jackson Immunoresearch, West 
Grove, PA). For visualization, Alexa Fluor 488 goat anti-rabbit IgG (Life Technologies, 
Zug, Switzerland, A-11008) or Alexa Fluor 594 donkey anti-rat IgG (Life Technologies, 
A-21209) was applied. All sections were mounted in Dako Fluorescent Mounting 
Medium (Dako). DNA was stained with 4’,6-diamidino-2-phenylindole (DAPI). Pictures 
were taken with a ×63 oil immersion objective (1.4 numerical aperture; Leica 
Microsystems, Heerbrugg, Switzerland). A CLSM Leica SP5 microscope (Leica 
Microsystems) attached to a diode and an argon laser was used to provide excitation 
at 405 nm, 488 nm and 561 nm wavelengths. The emitted fluorescence light was 
detected via three adjustable photomultiplier detectors. Per brain section, two single 
images from randomly selected ROI were recorded and included in the quantification. 
The surface detection function within the Bitplane Imaris (Bitplane) software (Roth et 





Analysis of gene expression data 
The microarray data have been presented previously (Ahmad et al., 2014). Raw 
microarray data were calibrated and summarized using the hook method including 
quantile-normalization (Irizarry et al., 2003; Binder et al., 2008; Binder and Preibisch, 
2008). The expression value of each gene was transformed into log10-scale and 
centered with respect to its mean value averaged over all samples investigated (Wirth 
et al., 2011). Differential expression analysis was performed using pairwise 
comparisons of sample classes and by applying a shrinkage t-score combined with 
false discovery rate multiple test correction for judgement of significance (Wirth et al., 
2012). For functional analysis we applied gene set enrichment analysis based on 
predefined gene sets taken from the literature, from gene ontology classification 
schemes, or from gene lists determined in this study. All methods were implemented 
in the program opoSOM that was used for all analyses (Loffler-Wirth et al., 2015). 
 
STRING analysis 
Functional gene interactions were analysed with the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) Version 10 at http://string-db.org (Franceschini 
et al., 2013). High confidence settings were applied, integrating combined scores 
higher than 0.700. Cluster analysis was performed by application of the Markov Cluster 
algorithm (MCL).  
 
Fluorescence-activated cell sorting (FACS) expression analysis 
Cells were detached with StemPro Accutase (Thermo Scientific), washed and 
incubated for 20 minutes in the dark at 4 °C with antibodies targeting the following 
membrane proteins: rat anti-mouse CD274 (PD-L1) BV421 (564716, BD Pharmingen, 
1:50), rat anti-mouse CD273 (PD-L2) APC (560086, BD Pharmingen, 1:50). Dead cell 
labelling was performed during surface staining by adding Zombie Aqua (423102, 
Biolegend, 1:100) to the antibodies mix. FACS was performed with a FACSVerse (BD, 
Biosciences). Dead cells were gated out and signal intensity was calculated as the 
ratio of the median fluorescence intensity (MFI) of the specific antibody and the isotype 






Intracellular cytokine staining 
Lymphocytes were isolated from the organ of interest or harvested from in vitro culture. 
For each staining at least 1 million cells were taken. In some cases, lymphocytes were 
re-stimulated in medium containing ionomycin (1:2000) (I0634, Sigma Aldrich), PMA 
(1:2000) (P-8139, Sigma Aldrich) and GolgiPlug/GolgiStop (1:1000) (555029, 554724, 
BD Biosciences) for 4-6 hours at 37°C. Surface staining was performed by incubating 
cells for 20 minutes at 4 °Cin the dark, using the following antibodies diluted in PBS: 
anti-mouse CD4 Pacific Blue (100428, Biolegend, 1:100), anti-mouse CD8a APC 
(100712, Biolegend, 1:100). Dead cell labelling was performed during surface staining 
by adding Zombie Aqua (423102, Biolegend, 1:100). Cells were then fixed and 
permeabilized with BD Cytofix/Cytoperm Fixation/Permeabilization Kit (554714, BD 
Biosciences), and stained intracellularly, following manufacturer’s instructions, with the 
following antibodies: anti-mouse IFN-γ PE (505808, Biolegend, 1:200), anti-mouse IL-
2 PerCP/Cy5.5 (503822, Biolegend, 1:25), and anti-mouse IL-10 PerCP/Cy5.5 
(505028, Biolegend, 1:25). Samples were analyzed with a FACSVerse (BD, 
Biosciences) and subsequently, data were analysed with FlowJo software (TreeStar). 
 
Nuclear transcription factor staining 
Lymphocytes were isolated from the organ of interest or harvested from in vitro culture. 
For each staining at least 1 million cells were taken. Surface staining was performed 
incubating cells for 20 minutes at 4 degrees in the dark, using the following antibodies 
diluted in PBS: anti-mouse CD4 Pacific Blue (100428, Biolegend, 1:100), and anti-
mouse CD25 APC (101910, Biolegend, 1:50). Dead cell labelling was performed 
during surface staining by adding Zombie Aqua (423102, Biolegend, 1:100). Cells were 
then fixed and permeabilized with FoxP3/Transcription factor staining buffer set (00-
5523, eBiosciences) and stained following manufacturer’s instructions with rat anti-
mouse FoxP3 PE antibody (12-5773-82, eBiosciences, 1:50). Samples were read with 
a FACSVerse (BD, Biosciences) and subsequently, data were analysed with FlowJo 
software (TreeStar). 
 
Cell cytotoxicity assay 
Immune-mediated glioma cell lysis was determined using a flow cytometry-based 
cytotoxicity assay. Target cells were stained with PKH-26 (Sigma-Aldrich) for 3 min 




indicated for 4-6 h. Subsequently, live/dead staining was performed with Zombie Aqua 
Fixable Viability Kit (BioLegend) followed by assessment of target cell lysis by flow 
cytometry. Specific cell lysis was expressed as percentage of dead cells within the 
PKH-26-positive target cells, corrected for spontaneous background lysis. 
    
Statistical analyses 
All in vitro data are representative of experiments performed in three independent 
experiments with similar results. Statistical significance was assessed using either two-
sided unpaired Student’s t-test or one-way ANOVA with Tukey’s post hoc test for 
multiple analysis. Quantitative data are represented as mean ± standard deviation (SD) 
for in vitro or standard error (SEM) of the mean for in vivo experiments. A p value below 
0.01 was considered significant. Kaplan Meier survival curves generated from the 
animal studies were analyzed using the log-rank test or the Gehan-Breslow-Wilcoxon 
test. A p value below 0.05 was considered significant. All statistical analyses were 
























5. Aims of the doctoral thesis 
Project 1 
Previous studies from our laboratory and many pieces of evidence described by others, 
have established a tight connection between the VEGF and TGF-β pathways. Indeed, 
they interdependently regulate several glioblastoma malignant features such as 
angiogenesis, immunosuppression, stem cell maintenance and invasion (described 
above). Furthermore, TGF-β is a well-known upstream regulator of VEGF expression. 
All these observations point to the possibility that TGF-β signalling may supply VEGF 
functions during anti-angiogenic therapy. 
 
Aim 1: To investigate a potential crosstalk between the VEGF and TGF-β signalling 
pathways in murine glioma cell lines in vitro. 
Aim 2: To investigate whether co-targeting of VEGF and TGF-β will prevent or delay 
tumor progression in syngeneic murine experimental glioma models in vivo. Moreover, 
in case co-treatment will provide synergy in vivo, we plan to investigate which 
molecules and cell populations are involved in the process.  
 
Project 2 
The activity of checkpoint inhibition in glioblastoma is yet to be determined. Preclinical 
studies have demonstrated that these therapies may work best when combined with 
other agents targeting redundant immunosuppressive pathways. Several studies have 
shown that TGF-β is a master regulator of glioblastoma-induced immunosuppression. 
Thus, we reasoned that inhibition of the TGF-β pathway could improve the efficacy of 
PD-1 blockade.   
 
Aim 1: Determine PD-L1 and PD-L2 expression in murine glioma cells and determine 
whether their expression can be modulated by different stimuli. 
Aim 2: To investigate whether dual targeting of the PD-1 and TGF-β pathways elicits 









6. Results  
 
6.1 Limited role for transforming growth factor-β pathway activation-mediated 
escape from VEGF inhibition in murine glioma models 
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6.1.1 Results project 1 
 
Characterization of VEGF and TGF-β1/2 ligand/receptor expression in mouse 
glioma cells 
VEGF-A (VEGF) mRNA was constitutively expressed by all four murine glioma cell 
lines, with the highest levels in GL-261 and SMA-560. In contrast, the highest levels of 
protein release were observed in SMA-540 and SMA-560 (Figure 11A). VEGFR1 
mRNA was expressed in all cell lines and protein levels correlated well, with highest 
levels in SMA-560. SMA-560 showed the highest VEGFR2 mRNA levels followed by 
SMA-540, and protein was only detected in SMA-540 and SMA-560 (Figure 11B). 
TGF-β1/2 mRNA was abundant in all four models. There was no apparent correlation 
between mRNA and protein levels, and TGF-β1 consistently exceeded TGF-β2 protein 
levels in the supernatant. TGFβR2 and ALK-5 were expressed in all models at variable 
levels, with correlation between mRNA and protein (Figure 11C,D). We also examined 
ex vivo tumoral mRNA expression of ligands and receptors, using syngeneic normal 
brain tissue (NBT) of VM/Dk and C57BL/6 mice as a reference. In vitro maintained 
monolayer cultures (MC) and mouse gliomas in vivo (T) showed similar VEGF mRNA 
levels (Figure 12A). Compared with MC, there were higher VEGFR1 mRNA in SMA-
497 and GL-261, and higher VEGFR2 mRNA levels in all models in vivo (Figure 
12B,C), suggesting a major contribution from tumor blood vessels or up-regulation of 
expression in tumor cells in vivo. Immunohistochemical stainings of VEGFR2 levels 
revealed a major contribution from tumor cells, even masking a typical vessel staining 
pattern, which, however, became readily visible in tumors stained for CD31 (see below) 
(Figure 13A,B). 
TGF-β1 but not TGF-β2 mRNA was enhanced in vivo in SMA-497, SMA-560 and GL-
261. While ALK-5 mRNA was consistently increased in vivo, there was a mixed pattern 
for TGFβR2 mRNA expression with increased expression in SMA-560, and a trend for 
















          
Figure 11. Expression of VEGF and TGF-β pathway ligands and receptors in mouse glioma 
models in vitro. SMA-497, SMA-540, SMA-560 and GL-261 cells were studied for gene 
expression. A. VEGF expression determined by RT-PCR for mRNA (top) and by ELISA for protein 
in the supernatant (bottom) in vitro. B. VEGFR1,2 expression determined by RT-PCR (top) and 
immunoblot (bottom) in vitro. C. TGF-β1/2 expression determined by RT-PCR (top) and ELISA in 
the supernatant (bottom) in vitro. D. TGF-βR2 and ALK-5 expression determined by RT-PCR (top) 
and immunoblot (bottom) in vitro. Values of densitometric analysis relative to β-actin are shown 
below the immunoblot panels in B and D. 
Figure 12. VEGF pathway ligand and receptor expression in experimental mouse gliomas in 
vivo. A-C Explanted SMA-497, SMA-540, SMA-560 or GL-261 mouse tumors (T) were studied for 
VEGF and VEGFR1,2 mRNA expression. MC and normal brain tissue of the respective mouse strain 
(VM/Dk or C57BL/6) served as references. (A) VEGF, (B) VEGFR1, (C) VEGFR2. Three ex vivo tissue 
samples per group were analysed. Data are expressed as mean and SD (*p<0.05, **p<0.01, unpaired 







Figure 13. VEGFR2 immunofluorescence in experimental mouse gliomas in vivo. 
Immunofluorescent stainings of VEGFR2 in mouse glioma tissues (A) and NBT (B) were performed 







Modulation of VEGF and TGF-β1/2 signaling in vitro 
We observed an increase in pVEGFR1 levels in response to exogenous VEGF in SMA 
but not in GL-261 glioma cells. pVEGFR2 was increased upon VEGF stimulation in 
SMA-540 and SMA-560 (Figure 15A). An increase in pSMAD2 was observed in all 
models after exposure to exogenous TGF-β2. LY2157299 attenuated constitutive and 
induced SMAD2 phosphorylation (Figure 15B). Neither VEGF pathway inhibition using 
Figure 14. TGF-β pathway ligand and receptor expression in experimental mouse gliomas in 
vivo. A-D Explanted tumors (T) were studied for TGF-β1/2, TGFβR2 and ALK-5 mRNA expression. 
MC and normal brain tissue of the respective mouse strain (VM/Dk or C57BL/6) served as references. 
(A) TGF-β1, (B) TGF-β2, (C) TGFβR2, (D) ALK-5. Three ex vivo tissue samples per group were 




B20 nor relevant concentrations of cediranib nor TGF-β pathway inhibition by 
LY2157299 affected viability or clonogenicity (Figure 16A,B). 
 
 
Figure 15. VEGF and TGF-β signaling in mouse glioma cells in vitro. A. pVEGFR1,2 levels after 
VEGF stimulation (400 ng/ml, 5 min) were assessed by immunoblot. B. pSMAD2 levels of cells 
either treated with 1 µM LY2157299 or 2 ng/ml TGF-β2 or both (SMA-540, SMA-560 for 3 h, SMA-
497, GL-261 for 24 h) were analyzed. C. pSMAD2 levels were assessed under normoxic or hypoxic 
conditions (24 h, 1% O2). Values of densitometric analysis of pVEGFR and pSMAD2 protein levels, 







Figure 16. VEGF and TGF-β signaling effects on viability and clonogenicity of mouse glioma 
cells in vitro. Mouse glioma cells were exposed to LY2157299 (24 h, 1 µM), cediranib (24 h, 100 
nM) or B20 (24 h, 100 µg/ml) A. Viability was assessed by trypan blue exclusion assay. B. 
Clonogenic survival was assessed by measuring cell density via crystal violet staining. Quantitative 
data are expressed as mean and SEM (***p<0.001, one-way ANOVA followed by Tukey’s post hoc 




Murinized bevacizumab prolongs survival in SMA-540, SMA-560 and GL-261 
glioma models 
We next determined single agent activity of B20 treatment in the four mouse glioma 
models. Histological analyses of tumors harvested when the first clinical symptoms 
occurred (early-stage) revealed reduced tumor volumes in all models except SMA-497. 
Tumor volume reduction was not paralleled by changes in Ki-67 labeling. Solvent-
treated tumors possessed well-delineated margins whereas tumor borders in the B20 
treatment groups were frayed and surrounded by numerous smaller satellites in all 
models (Figure 17A,B). The number of intratumoral vessels was decreased in SMA-
540, SMA-560 and GL-261, but not in SMA-497 (Figure 17C). Vessel morphology was 
specifically changed in GL-261 with decreased vessel diameter. CA IX staining as a 
surrogate marker for hypoxia was strongly induced in SMA-540 and SMA-560, but still 
not reaching constitutive levels of the SMA-497 model (Figure 17D). In general, CA IX 
staining was inversely related to CD31 labeling, confirming that hypoxia develops with 
increasing distance from blood vessels (Figure 18). Finally, B20 prolonged survival in 
the SMA-540, SMA-560 and GL-261 models, but not in SMA-497 (Figure 19; Table 1). 
Our hypothesis of induced activation of the TGF-β pathway as an escape route from 
VEGF inhibition led us to predict increased pSMAD2 levels in B20-treated tumors at 
least at progression. However, we observed decreased pSMAD2 levels in 2 of 4 mouse 
models in vivo, and no change in the other two models, in fact, there was an 
association between decreased pSMAD2 levels and benefit from B20 (Figure 20A). 
This decrease in pSMAD2 levels was observed in tumor cells and tumor-infiltrating 
leukocytes. Tumor cells were more frequently pSMAD2-positive than host cells 
indicating that tumor cells may be more responsive to TGF-β than host cells (Figure 
20B). Further, we noted that, in sharp contrast to the initial hypothesis of B20-triggered 
hypoxia followed by hypoxia-induced, TGF-β-mediated invasiveness, induction of 
hypoxia and reduction of pSMAD2 were seen in the same models. Accordingly, all four 
cell lines responded to hypoxia with decreased pSMAD2 levels in vitro, too (Figure 
15C). Bioinformatic analyses of previously published data focusing on angiogenesis 
gene sets (Table 2) revealed that SMA-497 express high levels of genes involved in 
angiogenic escape pathways (Figure 21; Table 3) (Ahmad et al., 2014). Unsupervised 
clustering of significantly regulated genes further revealed that genes up-regulated in 
SMA-497 were mainly down-regulated in GL-261, and vice versa (Figure 21; encircled 




the differential activation or down-regulation of genes of the angiogenic genesets in 




Figure 17. Differential effects of murinized bevacizumab on angiogenesis and growth of 
murine gliomas. Syngeneic mice intracranially implanted with SMA-497, SMA-540, SMA-560 or 
GL-261 cells were treated twice weekly with 5 mg/kg B20 or PBS from day 7 on. A-D Brain sections 
from animals sacrificed when the first mice became symptomatic were stained with (A) H&E or by 
immunohistochemistry and quantified for (B) Ki-67, (C) CD31, or (D) CA IX. Data are expressed as 
mean and SEM (*p<0.05, **p<0.01, ****p<0.0001, unpaired student t-test, B20 versus solvent). Size 







 Cell line  
 SMA-497 SMA-540 SMA-560 GL-261 
 Median survival (range) [days]  
Treatment     
Control 14 (13–17) 31 (27–44) 14.5 (12–14) 20 (19-24) 
B20 15 (13–20) 48 (41–55) 32.5 (20->40*) 27.5 (24->40*) 
 ns p=0.0009 p=0.0007 p=0.0025 
Control 14 (12–18) 42 (27->60*) 13 (11–14) 17 (15 – 22) 
LY2157299 14 (12–19) >60 (44->60*) 17 (12 – 18) 17 (15–22) 
 ns ns p=0.014 ns 
Control 15 (14–16)   19.5 (17–44) 
B20 15 (14–17)   28 (22–41) 
LY2157299 15.5 (14–17)   19 (17–32) 
B20+LY2157299 16 (15–17)   33 (25–41) 
 ns   p=0.0166 
(cotreatment vs B20) 
p<0.0001 
(cotreatment vs LY) 
Figure 18. Vessel density and hypoxia in murine gliomas. Vessel density and tumor hypoxia in 
untreated murine SMA-497 or SMA-560 gliomas were assessed by immunofluorescent stainings for 
CA IX (green) and CD31 (red), using nuclear counterstaining with DAPI (blue). Merged images are 
provided as indicated in right images of each row. Size bars correspond to 100 µM. 
* censored because experiment was terminated at day 40 or day 60 
Table 1. Sensitivity of mouse glioma models to VEGF antibody B20 or the TGFβR1 (ALK-5) 








Figure 19. Differential effects of murinized bevacizumab on survival of murine gliomas. 
Kaplan-Meier survival curves of glioma-bearing mice (log-rank test, considered significant for 
p<0.05).  









Figure 20. pSMAD2 levels in murine gliomas. Syngeneic mice intracranially implanted with SMA-
497, SMA-540, SMA-560 or GL-261 cells were treated twice weekly with 5 mg/kg B20 or PBS from 
day 7 on. A. Brain sections from animals sacrificed when the first mice became symptomatic were 
stained for pSMAD2. B. pSMAD2 levels were determined in tumor cells and leukocytes upon B20 
treatment in the SMA-560 model in vivo. Immunofluorescent stainings were performed for pSMAD2 
(green) and CD45 (red), again using DAPI as a counterstain. Merged images are provided as 
indicated in right images of each row. Size bars correspond to 50 µM (A) and 100 µM (B). 
Figure 21. Angiogenic gene expression heatmap. The heatmap was obtained by unsupervised 
comparison of genes differentially expressed in the four mouse glioma cell lines. The heatmap indicates 
high to low expression levels as red to blue color coding. Up- or downregulated gene clusters in SMA-






Figure 22. Gene cluster analysis. A.B. Functional interactions between genes up-regulated in the 
angiogenic profiles of (A) SMA-497 and (B) GL-261 (top) or down-regulated in GL-261 (bottom) were 
analyzed in Affymetrix micro-array based gene expression profiling by STRING analysis. Interactions with 
high confidence score of 0.700 were integrated to the interactome. Clusters were determined by MCL 

























































































































































































LY2157299 prolongs survival in the SMA-540 and SMA-560 murine glioma 
models 
Next, we determined single agent activity of LY2157299 in the four mouse glioma 
models. Histological analyses of tumors harvested when the first clinical symptoms 
occurred revealed a trend towards reduced tumor volumes only in SMA-560 (Figure 
23A). We then explored whether exposure to LY2157299 suppressed pSMAD2 as a 
surrogate marker of TGF-β pathway activity. pSMAD2 levels were decreased by 
LY2157299 in all models, confirmed by immunoblot in SMA-560 (Figure 23B). 
Intratumoral vessel density was unaffected in either model but vessel morphology was 
changed in all models, except SMA-497, towards a vasculature with decreased vessel 
diameter and lumina upon LY2157299 treatment (Figure 23C). LY2157299 prolonged 
survival in SMA-560 and SMA-540, but not SMA-497 or GL-261 (Figure 24;Table 1). 
Accordingly, transcriptomic analysis of TGF-β receptor signaling pathway gene sets 
(Table 4) showed SMA-540 and SMA-560 to be the cell lines with the highest TGF-β 
pathway activity (Fig. 25A, Table 5). The survival differences in the SMA-540 control 
groups in the studies reported in Figures 2 and 3 is explained by variations in the 
tumorigenicity in this model which is the least tumorigenic. Transcriptomic profiling also 
revealed that the most immunogenic tumors as defined by Gene Ontology, SMA-497 
and GL-261, exhibited differential clusters of up- and down-regulated genes involved 
in immune response pathways. Genes up-regulated in SMA-497 were mainly down-
regulated in GL-261, and vice versa (Fig. 25B encircled; Table 6,7). STRING analysis 
of the differentially regulated gene clusters visualized the differential activation or 
Angiogenesis-related genes 
up-regulated in SMA-497 
Angiogenesis-related genes 
up-regulated in GL-261 
Angiogenesis related genes 
down-regulated in GL-261 
 C3; Col1a1; Wnt5a; Lef1; 
Tbx3; Btg1; Vash2; Gata4; 
Tgfb2; Ddah1 
Hey1; Thbs1; Gata6 
Prl2c2; Lox; Sphk1 
CD34; Cyp1b1; Ntrk1 
Sfrp2; Angpt1; Vegfc; Cx3cl1; 
Bmp4; C3ar1 
Chd7; Serpine1; Sema3e; 
Notch1; Hc; Itgav; Brca1; 
Foxf1; Ramp2; Hey2; Alox12; 
Ptk2b; Adm2; Nrp1; Mfsd7b; 
Sphk2; Otulin; Ctsh; F3; 
Lama4; Mef2c; Pax6; Sash1; 
Fgf2; Atp7a 
Col1a1; Wnt5a; Lef1; Tbx3; 
Btg1; Vash2 
Gata4; Thbs1; Gata6 
Prl2c2; Lox; Sphk1 
C3; Ecm1; Rapgef3 
Gata2; Isl1; Aqp1;Eng 
Anxa3; Tgfbr3; Epha2 
Col1a2; Grem1;Cdh13 
Gpr124; CD34; Cyp1b1; Ntrk1; 
Sfrp2; Angpt1; Vegfc; Cx3cl1; 
Bmp4; C3ar1 
Table 3. Differentially regulated genes of angiogenic profiles of SMA-497 and GL-261 mouse 




down-regulation of genes of the immune response-related gene sets in SMA-497 and 







Figure 23. Differential effects of LY2157299 on pSMAD2 levels and angiogenesis of murine 
gliomas. Mice intracranially implanted with SMA-497, SMA-540, SMA-560 or GL-261 cells were 
treated daily with LY2157299 at 150 mg/kg or control solvent from day 7 on. A-C Data quantification 
and displaying of brain sections from animals sacrificed when the first mice became symptomatic. 
A. H&E. B. Immunohistochemical stainings of pSMAD2 (top) and protein levels determined by 
immunoblot (bottom). Values of densitometric analysis of pSMAD2 protein levels, relative to β-
actin, are shown below the immunoblot panels. C. CD31. Size bars within images correspond to 

























Figure 24. Differential effects of LY2157299 on the growth of murine gliomas. A. Kaplan-Meier 







Figure 25. TGF-β and immune response gene expression heatmaps. Heatmaps were obtained 
by unsupervised comparison of genes differentially expressed in the four mouse glioma cell lines for 
the TGF-β signaling (A) and immune response (B) pathways. The heatmaps indicate high to low 
expression levels as red to blue color coding. Up- or downregulated gene clusters in SMA-497 and 




















Figure 26. Gene cluster analysis. Functional interactions between genes up-regulated in immune 
response pathways in SMA-497 (A) and GL-261 (B, left) or down-regulated in GL-261 (B, right) were 
analyzed by Affymetrix micro-array based gene expression profiling using STRING analysis. 
Interactions with high confidence score of 0.700 were integrated to the interactome. Clusters were 
determined by MCL algorithm and presented with different node colors. Inter-cluster edges are 




































































































regulated in SMA-540 
TGF-β-related genes up-
regulated in SMA-560 
Tgfbr3; Tgfb1; Smurf1; Itgb5; 
Eng; Col1a2; Bambi; Bmp2; 
Col3a1; Skil; Ltbp4; Zyx: Smurf2 
Dusp22; Map3k1 
Fut8; Tgfbr3; Tgfb1 
Smurf1; Itgb5; Eng 
Table 4. Gene sets of TGF-β receptor signaling pathways as defined by Gene Ontology 
classification schemes.  
Table 5. Differentially regulated genes of TGF-β signaling pathways of SMA-540 and SMA-560 





































































































































































































Reciprocal modulation of the VEGF and TGF-β pathways in vitro                       
We next assessed the expression of ligands and receptors of the VEGF and TGF-β 
pathways in the mouse glioma models after reciprocal stimulation. First we explored 
whether modulation of VEGF signalling in glioma cells affected the TGF-β pathway. 
Exposure to exogenous VEGF, B20 or cediranib had no effect on TGF-β1/2 mRNA and 
protein levels (Figure 27A,B) or pSMAD2 levels (Figure 27C). Conversely, VEGF 
mRNA expression and protein release were induced by TGF-β2 in a LY2157299-
sensitive manner. VEGF mRNA expression was also increased in all cells in response 
to hypoxia whereas protein levels were increased in SMA-497, SMA-540 and GL-261 
and remained similar in SMA-560 (Figure 28A,B). Furthermore, we observed an 
increase in total VEGFR1 mRNA expression in response to TGF-β2 in SMA-497 and 
SMA-560 glioma cells which was decreased upon co-treatment with LY2157299 only 
in SMA-560. However, protein levels were increased in all models and this effect was 
blocked by LY2157299 (Figure 29A). VEGFR2 levels in response to TGF-β2 
stimulation, analyzed in SMA-540 and SMA-560 cells only, were increased upon 
stimulation in a LY2157299-sensitive manner (Figure 29B). Although LY2157299 alone 
reduced constitutive pSMAD2 levels (Figure 15B), it had no effect on constitutive 






genes up-regulated in SMA-
497 
Immune response-related 
genes up-regulated in GL-
261 
Immune response-related 
genes down-regulated in GL-
261 
Smad6; Map3k14 
Ccl9; Bmpr1a; Igf1r; 
Bmp6; Ccl8; Cd24a; Il15; Enpp2; 
Cx3cl1; Fcgrt; Ccl17; Cxcl1; Il7; 
Cxcl12 
Cxcl5; Cd1d1; thbs1 
Oasl2; Oas1g; Tgtp1 
Gbp6; Oas1b; Enpp1 
Ccl5; Cd274; H2−Bl 
Lst1; Mill2; Nrros 
Tnfsf10; Bpi; Psg17 
C7; H2−DMb2; Enpp3 
Ccl25; Tnfsf9; H2−Q4 
H2−K1; Oas3; H2−T23 
Azgp1; Tinagl1; Il18 
Smad3; Tnfrsf1b; Eda 
Lif; Cblb; Tgfbr3 
Colec12; ccl7 ; Cx3cl1; Fcgrt; 
Ccl17 ; Cxcl1; Il7; Cxcl12 ; 
Cxcl5; cd1d1 
Table 7. Differentially regulated genes of immunogenic profiles of SMA-497 and GL-261 mouse 







Figure 27.  Modulation of the TGF-β signaling pathway by VEGF in vitro. A.B. Modulation of TGF-
β1 (A) or TGF-β2 (B) mRNA (left) expression was determined by RT-PCR 24 h after exposure to VEGF 
(400 ng/ml), cediranib (100 nM) or B20 (100 µg/ml). Protein levels (right) were detected in 
corresponding supernatants by ELISA. Data are expressed as mean and SD (n=3) (one-way ANOVA 
followed by Tukey’s post hoc test, confidence interval 99%). C. pSMAD2 levels were assessed by 
immunoblot. Values of densitometric analysis of pSMAD2 protein levels relative to β-actin are shown 









Figure 28.  Modulation of VEGF-A by TGF-β signaling pathway in vitro. A.B. The cells were 
treated with TGF-β2 (2 ng/ml) or LY2157299 (LY) (1 µM) or both for 24 h. VEGF mRNA expression 
was assessed by RT-PCR (A). In parallel, VEGF protein levels were determined by ELISA (B). 
Hypoxia served as positive control for VEGF-A expression (***p<0.001, one-way ANOVA followed 
by Tukey’s post hoc test confidence interval 99%, treated versus SFM, ++p<0.01, +++p<0.001, 







Figure 29.  Modulation of VEGFR1-2 by TGF-β signaling pathway in vitro. A.B. VEGFR1/2 
mRNA (top) and protein (bottom) levels were assessed by RT-PCR and immunoblot, respectively. 
mRNA and ELISA data are expressed as mean and SD (n=3) (***p<0.001, one-way ANOVA 
followed by Tukey’s post hoc test confidence interval 99%, treated versus SFM, ++p<0.01, 
+++p<0.001, LY2157299 + TGF-β2 versus TGF-β2). Values of densitometric analysis of VEGFR 




Co-targeting of the VEGF and TGF-β pathways in vivo  
SMA-497 and GL-261 were chosen to explore a potential synergy between VEGF and 
TGF-β pathway inhibition. SMA-497 was chosen because it was refractory to either 
treatment as single agent, facilitating the detection of any possible synergy. GL-261 
was chosen because LY2157299 alone was not active whereas B20 was. A gain from 
co-treatment would indicate that the TGF-β pathway assumes a different role in the 
context of VEGF inhibition. There was no survival benefit from co-treatment in SMA-
497 whereas combination treatment was superior to either treatment alone in GL-261 




Early reductions of tumor volumes and blood vessel density were seen in GL-261, but 
not SMA-497, and only in the B20-containing regimens, with no modulation by 
LY2157299. The volume differences in early-stage GL-261 tumors were abolished in 
end-stage tumors. However, reduced blood vessel density was only maintained in the 
co-treatment group, but not in the B20-only end-stage tumors. Decreased vessel 
diameter and increased vessel wall thickness were observed with all therapeutic 
regimens in GL-261 (Figure 31A,B). ZO-1 was used as a marker for tight junction 
staining showing a more regular staining pattern indicative for a restoration of 
endothelial barrier integrity (Figure 32A-D). Co-treatment with LY2157299 prevented 
B20-induced increased tumor invasiveness in early stages, but this effect was 
abolished in end-stage tumors (Figure 31A, bottom). In GL-261, but not SMA-497 
gliomas, the reduction of pSMAD2 levels by LY2157299 alone was enhanced by co-
Figure 30. Effect of combined B20 and LY2157299 treatment in SMA-497 and GL-261 
syngeneic models in vivo. Syngeneic mice were intracranially implanted with SMA-497 or GL-261 
cells and treated twice weekly with 5 mg/kg B20 or daily with 150 mg/kg LY2157299 or corresponding 
solvents or both from day 7 on. Kaplan-Meier survival curves (Gehan-Breslow-Wilcoxon test, 




treatment with B20 in early-stage responsive and in end-stage resistant tumors. In 
contrast, pSMAD2 levels were increased in B20-treated end-stage tumors, consistent 
with the TGF-β pathway as an escape route from VEGF inhibition, and this was not 
seen with combined treatment (Figure 33A). There was no significant CA IX induction 
in either model in early-stage tumors whereas treatment resistance in the GL-261 co-
treatment group was accompanied by an increase in CA IX staining from 18% to 39% 
positive tumor areas (Figure 33B). Assessment of the role of TGF-β1/2 within 
angiogenesis gene clusters up-regulated in SMA-497 and GL-261 by STRING analysis 
revealed that TGF-β1/2 may interact with only a small subset of up-regulated genes in 
SMA-497. Conversely, both molecules are integrated in the main network of functional 
gene interactions in GL-261 (Figure 34), indicating a possible role of TGF-β in 





































Figure 31. Analysis of morphology and angiogenesis patterning in SMA-497 and GL-261 
syngeneic models treated with combined B20 and LY2157299 in vivo. Syngeneic mice 
intracranially implanted with SMA-497 or GL-261 cells were treated twice weekly with 5 mg/kg B20 or 
daily with 150 mg/kg LY2157299 or corresponding solvents or both. Early-stage refers to brain 
sections from animals sacrificed when the first mice became symptomatic and end-stage at the time 
point when each specific mouse developed neurological symptoms. A. Tumor volume (top) and 
morphological analysis by H&E (bottom). B. CD31+ capillaries density quantification (top) and 
immunohistochemical staining (bottom). Size bars corresponds to 100 µm. (***p<0.001, one-way 
ANOVA followed by Tukey’s post hoc test confidence interval 95%, treated versus solvent, 
+++p<0.001, B20+LY2157299 versus B20, ##p<0.01, B20+LY2157299 versus LY2157299). 
Figure 32. Analysis of tight junctions patterning in SMA-497 and GL-261 syngeneic models 
treated with combined B20 and LY2157299 in vivo. Syngeneic mice were intracranially 
implanted with SMA-497 or GL-261 cells and treated twice weekly with 5 mg/kg B20 or daily with 
150 mg/kg LY2157299 or corresponding solvents or both from day 7 on. A-D Staining of tumor 
sections to visualize vessel normalization was performed with DAPI (A. blue), CD31 (B. red) and 






















Figure 33. Analysis of pSMAD2 levels and hypoxia patterning in SMA-497 and GL-261 
syngeneic models treated with combined B20 and LY2157299 in vivo. Syngeneic mice 
intracranially implanted with SMA-497 or GL-261 cells were treated twice weekly with 5 mg/kg B20 
or daily with 150 mg/kg LY2157299 or corresponding solvents or both. Early-stage refers to brain 
sections from animals sacrificed when the first mice became symptomatic and end-stage at the time 
point when each specific mouse developed neurological symptoms. A. pSMAD2 H-score quantization 
(top) and immunohistochemistry representative images (bottom). B. CA IX percentage of stained area 
(top) and representative immunohistochemistry images (bottom). Size bars correspond to 50 µm (A) 
and 100 µm (B). (*p<0.05, **p<0.01, ***p<0.001, one-way ANOVA followed by Tukey’s post hoc test 
confidence interval 95%, treated versus solvent, +++p<0.001, B20+LY2157299 versus B20, 
##p<0.01, B20+LY2157299 versus LY2157299). 
Figure 34. Bioinformatic analysis of TGF-β1/2 interactome within angiogenesis gene clusters 
up-regulated in SMA-497 and GL-261. Gene cluster analysis. Functional interactions between 
TGF-β1/2 and genes upregulated in angiogenic profiles in SMA-497 (left) and GL-261 (right) were 
analyzed in Affymetrix micro-array based gene expression profiling by STRING analysis. Interactions 
with high confidence score of 0.700 were integrated to the interactome. Clusters were determined 





Differential host cell responses to VEGF/TGF-β co-targeting 
To generate a broad overview on host cell infiltration, we assessed frequencies of 
leukocytes (CD45+), T cells (CD4+ and CD8+) and macrophages/microglia (CD11b+) in 
mono- and co-treated SMA-497 and GL-261 early- and end-stage tumors (Figure 
35,36). In GL-261, only in early- but not in end-stage tumors, increased infiltration of 
CD11b+ cells upon B20 alone and increased numbers of cytotoxic T (CD8+) cells upon 
co-treatment were observed (Figure 36A). Resistance to co-treatment was 
accompanied by decreased infiltration of CD45+ and CD11b+ cells in GL-261 end-stage 
gliomas when compared to solvent or B20 mono-treatment (Figure 35A, 36B). 
pSMAD2 was detected in tumor cells rather than host leukocytes in GL-261 end-stage 
tumors. Due to the higher proportion of pSMAD2-positive tumor cells versus infiltrating 
leukocytes, tumor cells were more affected by decreased pSMAD2 levels, although 
levels in single leukocytes were altered similarly, with a decrease upon LY2157299 
and combined treatment, and an increase by B20 alone (Figure 37A-D).  
 

























 cells infiltration in combined B20- and 
LY2157299-treated syngeneic models in vivo. Syngeneic mice intracranially implanted with SMA-
497 or GL-261 cells were treated twice weekly with 5 mg/kg B20 or daily with 150 mg/kg LY2157299 
or corresponding solvents or both. Early-stage refers to brain sections from animals sacrificed when 
the first mice became symptomatic and end-stage at the time point when each specific mouse 
developed neurological symptoms. A. CD45+ cells percentage (top) and representative 
immunohistochemistry images (bottom). B. CD4+ number of cells per field (top) and representative 
immunohistochemistry images (bottom). Size bars correspond to 50 µm. (*p<0.05 ANOVA followed 















pSMAD2 levels in response to bevacizumab treatment in human glioblastoma 
We also analysed human glioblastoma patients who underwent further surgery upon 
failure of bevacizumab. As groups, neither refractory tumors of 9 non-bevacizumab-
treated patients, nor those of 5 patients failing on a bevacizumab-containing regimen, 




 cells infiltration in combined B20- and 
LY2157299-treated syngeneic models in vivo. Syngeneic mice intracranially implanted with SMA-
497 or GL-261 cells were treated twice weekly with 5 mg/kg B20 or daily with 150 mg/kg LY2157299 
or corresponding solvents or both. Early-stage refers to brain sections from animals sacrificed when 
the first mice became symptomatic and end-stage at the time point when each specific mouse 
developed neurological symptoms. A. CD8+ number of cells per field (top) and representative 
immunohistochemistry images (bottom). B. CD11b+ percentage of cells (top) and representative 
immunohistochemistry images (bottom). Size bars correspond to 50 µm. (*p<0.05 and ***p<0.001 
one-way ANOVA followed by Tukey’s post hoc test confidence interval 95%, treatment versus solvent, 
#p<0.05, B20+LY2157299 versus LY2157299, +p<0.05 B20+LY2157299 versus B20). 
Figure 37. Modulation of pSMAD2 levels and tumor immune cell infiltration in B20 and 
LY2157299 co-treated GL-261 syngeneic model in vivo. Brain sections (end-stage) were 
examined. Staining of tumor sections was assessed with DAPI (A. blue), pSMAD2 (B. green) and 
CD45 (C. red). Merged images are shown in (D). CD45+/pSMAD2+ leukocytes are marked by arrow 




exhibited an increase or decrease in pSMAD2 levels whereas vessel density was 
decreased in the latter group (Figure 38,39). 
 
 
Figure 38. pSMAD2 levels in non-bevacizumab-treated patients. pSMAD2 levels were assessed 
by immunofluorescence microscopy in primary and recurrent tumor tissue of patients treated with non-
bevacizumab regimens (A). Size bars correspond to 20 µM. Quantification of fluorescent images of 







Figure 39. pSMAD2 levels in bevacizumab-treated patients. pSMAD2 levels were assessed by 
immunofluorescence microscopy in primary and recurrent tumor tissue of patients treated with 
bevacizumab-containing regimens (A). Size bars correspond to 20 µM. Quantification of fluorescent 
images of the cohort is provided in B. (C) Vessel density scores. Data are expressed as mean and SEM 




6.2 Results project 2 
 
Characterization of PD-L1 and PD-L2 basal expression and modulation by TGF-
β signalling in mouse glioma cells 
PD-L1 was constitutively expressed at mRNA level in all four murine glioma cell lines 
with highest expression in GL-261 cells. Protein presence on the cell surface was 
assessed by flow cytometry and showed low, but detectable levels in all cell lines. PD-
L2 mRNA was expressed only in SMA-497 cells, yet, this did not translate in protein 
expression as PD-L2 was not detected on the surface of any cell line (Figure 40A,B). 
Subsequently, we examined whether TGF-β regulates PD-L1 and PD-L2 expression 
levels. Neither treatment with a TGFβRI inhibitor (SD-208) nor stimulation with 
recombinant TGF-β2 changed the expression of the PD-1 ligands. IFN-γ stimulation 
was used as positive control for PD-L1 induction, however, it did not affect PD-L2 
protein surface expression (Figure 40C,D).  
      






Dual blockade of PD-1 and TGF-β pathways increases cytokine production of 
CD4+ and CD8+ T cells challenged with syngeneic tumor cells   
To investigate whether inhibition of the PD-1 and TGF-β pathway can reverse glioma 
cell-mediated T cell immunosuppression, we set up an in vitro co-culture model. Mouse 
glioma cells were co-cultured with polyclonally activated syngeneic lymphocytes in the 
presence or absence of anti-PD1, LY2157299 or a combination thereof (Figure 41A,B). 
After 4-6 days, floating lymphocytes were harvested to determine intracellular cytokine 
levels. In a first set of experiments, CD4+ and CD8+ T cell production of IFN-γ and IL-
2 was assessed in co-culture systems using SMA-497, SMA-540 or GL-261 cells. 
Single agent treatment with either anti-PD1 or LY2157299 increased IFN-γ production 
of both T cell populations with a similar trend in all tested cell lines. Combinatorial 
treatment resulted in highest IFN-γ production compared to either treatment alone 
(Figure 42A,B). Differently, IL-2 production was consistently low in SMA-497 and SMA-
540 cells and was not affected by any treatment. In the GL-261 model, there was higher 
basal production of IL-2 compared to SMA cell lines, which was further elicited in CD4+ 













Figure 40. Basal and modulated expression of PD-L1 and PD-L2 in mouse glioma cells. A. PD-
L1 and PD-L2 mRNA expression was determined by RT-PCR. B. Presence of the protein on the 
surface was assessed by flow cytometry. Modulation of PD-L1 (C) and PD-L2 (D) protein expression 
by exposure to SD-208 (1 μM), recombinant TGF-β2 (2 ng/ml) or IFN-γ (100 U/ml) stimulation was 







Figure 41. In vitro co-culture system and gating strategy. A. Graphic representation of the co-
culture model. Actively growing 2x105 tumor cells were co-cultured for 4-6 days with 106 syngeneic 
activated lymphocytes (2 μg/mL concanavalin A) in the absence or presence of anti-PD1 (10 μg/ml), 










Figure 42. Effects of dual PD-1 and TGF-β pathway blockade on T cell cytokine production. 
Actively growing 2x105 tumor cells were co-cultured for 4-6 days with 106 syngeneic activated 
lymphocytes (2 μg/mL concanavalin A) in the absence or presence of anti-PD1 (10 μg/ml), TGFβRI 
inhibitor (LY2157299, 1μM) or a combination thereof. After co-culture, lymphocytes were re-
stimulated for 4 h in the presence of ionomycin (500 ng/ml), phorbol-12-myristate-13-acetate (PMA, 
50ng/ml) and 1:1000 final concentration of Golgiplug (containing brefeldin A) and Golgistop 
(containing monensin). Percentage of IFN-γ+ (top) or IL-2+ (bottom) cells gated on CD4 (A) or CD8 
(B) positive cells after co-culture with the indicated mouse glioma cell line (*P < .05, **P < .01, ***P < 
0.001 one-way ANOVA followed by Tukey’s post hoc test 95% CI, isotype vs treatment; #P < .05, ##P 




Effects of dual PD-1 and TGF-β pathway blockade on T cell subsets induction 
Using our in vitro model system, we further explored whether glioma cells can induce 
the generation of inhibitory Treg cells. We found in the GL-261 model that around 30% 
of the CD4+ CD25+ cells expressed the Treg-defining transcription factor FoxP3 (Figure 
43A). Conversely, no CD4+ CD25+ FoxP3+ cells were generated during co-culture of 
SMA-497 and SMA-540 with activated syngeneic lymphocytes. Importantly, Treg cell 
induction in the GL-261 was dampened by anti-PD1 or anti-TGFβRI, with co-treatment 
being the most effective (Figure 43A). Furthermore, analysis of T cells after 4-6 days 
of co-culture with syngeneic tumor cells revealed that anti-PD1 blockade favors either 
survival or expansion of CD8+ cells compared to CD4+ cells (Figure 43B).  
 
Dual blockade of the PD-1 and TGF-β pathway increases T cell-mediated 
cytotoxicity against GL-261, but not SMA-497 or SMA-540 cells.   
T cells harvested after 4-6 days of co-culture with syngeneic tumor cells were 
challenged with naïve syngeneic tumor cells in a cell cytotoxicity assay. While T cells 
isolated from a co-culture with GL-261 cells containing anti-PD1 or anti-TGFβRI alone 
did not improve killing rates compared to untreated control, combined targeting 
significantly improved tumor cell lysis (Figure 43C). No differences among the 




          
 
 
Figure 43. Effects of dual PD-1 and TGF-β pathway blockade on regulatory T cell induction, T 
cell populations and T cell-mediated cytotoxicity. Actively growing 2x105 tumor cells were co-
cultured for 4-6 days with 106 syngeneic activated lymphocytes (2 μg/mL concanavalin A) in the 
absence or presence of anti-PD1 (10 μg/ml), TGFβRI inhibitor (LY2157299, 1 μM) or both. A. 
Percentage of regulatory T cells defined as CD4+ CD25+ FoxP3+. B. Percentage of CD4+ and CD8+ 
cells was calculated on the total pool of live cells harvested from the co-culture. C. Lymphocytes 
isolated after 4-6 days of co-culture were challenged with tumor cells pre-stained with PKH-26 at 
different effector to target (E:T) ratios as indicated for 4 h. Cell specific lysis is expressed as 
percentage of dead cells within the PKH-26-positive target cells, corrected for spontaneous 
background lysis. (**P < .01, ***P < 0.001 one-way ANOVA followed by Tukey’s post hoc test 95% 





Interactions between human tumors and their specific microenvironment determine 
growth characteristics and responses to radiotherapy or pharmacotherapy (Hanahan 
and Weinberg, 2011). This notion is particularly true for glioblastoma, which typically 
contains major host cell infiltrates that probably support rather than limit tumor growth 
(Murdoch et al., 2008; Maes et al., 2013; Vom Berg et al., 2013). 
In project 1, we focused on two cytokine-dependent signalling pathways attributed a 
major role in the pathogenesis of glioblastoma, VEGF and TGF-β, using a panel of 
syngeneic mouse gliomas as model systems (Ahmad et al., 2014).  
Responsiveness to VEGF and TGF-β stimulation as assessed by VEGFR and SMAD2 
phosphorylation as well as a positive regulation of VEGF by TGF-β, but not vice versa, 
was confirmed in vitro (Figure 11;27-29). Inhibition of neither pathway has prominent 
effects on glioma cell viability or growth in vitro (Figure 16) although growth 
suppressive properties have been reported for TGF-β1 in the SMA-560 model (Ashley 
et al., 1998). 
There was differential responsiveness to B20-mediated VEGF inhibition alone. While 
high expression of VEGF and VEGFR is consistent with responsiveness of SMA-560, 
the responsiveness of SMA-540 was less well explained, and the expression levels of 
VEGF in GL-261 did not translate into superior efficacy of B20. The responsiveness of 
GL-261 despite unaltered proliferation and hypoxia is consistent with direct induction 
of cell death by VEGF inhibition in some mouse glioma models (Scholz et al., 2015; 
Pitter et al., 2016). A high constitutive level of hypoxia and failure to reduce blood 
vessel density in response to B20, consistent with VEGF-independent angiogenesis, 
were prominent features of the refractory SMA-497 model. Of note, full suppression of 
angiogenesis was not achieved in any model (Figure 17). Although all SMA lines were 
derived from one tumor, they exhibited major variation in response to different 
treatment settings that were tentatively linked to differential transcriptomics specifically 
among angiogenesis-related gene sets (Figure 21;Tables 2-3). 
The TGFβR1 inhibitor LY2157299 was active pharmacodynamically as assessed by a 
decrease of pSMAD2 levels in vivo, although no full suppression was achieved, 
indicating either insufficient pharmacodynamic properties and target coverage, or ALK-
5-independent pathways maintaining pSMAD2 phosphorylation, or both (Figure 23). 
The two models responsive to LY2157299 in vivo, SMA-540 and SMA-560, exhibited 




25). Similar to anti-angiogenic therapy, also TGF-β antagonism has been linked to 
vascular normalization and improved drug delivery (Liu et al., 2012). Accordingly, we 
observed morphological changes related to vascular normalization in tumor vessels 
upon LY2157299 treatment in all models, consisting of increased vessel wall thickness 
and decreased vessel diameter (Figure 23). It is tempting to link these uniform changes 
in blood vessel morphology, induced by LY2157299, to the effects of TGF-β on VEGF 
and VEGFR expression in vitro (Figure 23;28;29). A transcriptional profiling study of 
human glioblastoma vessels indicated key roles in the process of pathological 
angiogenesis for VEGF-A and TGF-β2, and suggests that TGF-β inhibition may 
represent a promising option as anti-angiogenic agent (Dieterich et al., 2012). The 
decrease in pSMAD2 levels in response to hypoxia in vitro and to hypoxia in 
association with B20 treatment in vivo in two of three responsive models was surprising 
(Figure 15;17) since no evidence suggests that the TGF-β pathway is negatively 
regulated by hypoxia. Interestingly, pSMAD2 levels positively correlated with tumor 
proliferation assessed by Ki-67 staining in human glioblastoma (Bruna et al., 2007). 
Accordingly, we also found parallel changes in the levels of both markers as shown by 
Ki-67 and pSMAD2 stainings upon B20 monotherapy (Figure 17). 
VEGFR inhibition in vitro did not decrease pSMAD2 levels in any cell line (Figure 27). 
Yet, the synergistic suppression of pSMAD2 levels by B20 and LY2157299 co-
treatment in early-stage tumors may suggest that anti-VEGF therapy leads to a 
vascular normalization process,  thereby improving LY2157299 delivery to the tumor. 
Importantly, increased pSMAD2 levels in end-stage tumors with B20 treatment alone 
are consistent with the hypothesis that enhanced TGF-β activity might promote 
eventual escape from VEGF inhibition at least in the GL-261 model. 
Immunohistochemical analysis of orthotopic U87MG gliomas had revealed increased 
TGF-β protein levels upon anti-VEGF treatment, too (Piao et al., 2012a).  
Increased levels of CD11b-positive macrophages/microglia have been linked to 
refractoriness to anti-VEGF treatment (Shojaei et al., 2007) and attributed a role in the 
VEGF-independent restoration of tumor vessels by vasculogenic, but not angiogenic 
processes (Kioi et al., 2010). Supporting this concept, we observed that co-targeting 
VEGF and TGFβR1 decreased the numbers of intratumoral CD11b+ cells and that 
tumors failed to re-vascularize compared to B20 alone in GL-261 end-stage tumors 
(Figure 36). Similarly, co-inhibition of VEGF and the Ang-2 pathway provided improved 




model (Scholz et al., 2015). Possibly, targeting TGF-β alters CD11b+ cell recruitment 
via interacting with the CXCR4/C-X-C motif chemokine ligand (CXCL)12 axis since 
VEGFR inhibitors can up-regulate the chemokine CXCR4 in glioblastoma cells by a 
TGF-β-dependent mechanism (Pham et al., 2015) and since TGF-β up-regulates 
CXCR4 expression in monocytes, macrophages, T naïve cells and other immune cell 
populations (Wang et al., 2001; Franitza et al., 2002). 
Altogether, according to our analysis in the GL-261 model, the tumor-promoting role of 
TGF-β would relate more to facilitating angiogenesis or vasculogenesis than to 
promote a more invasive phenotype even when combined with VEGF antagonists. This 
is because B20-treated tumors were more invasive early on when pSMAD2 levels were 
still low and because co-treatment with LY2157299 still suppressed tumor vasculature 
in end-stage disease (Figure 17;31). Yet, B20-induced hypoxia may ultimately promote 
lactate dehydrogenase activity (Fack et al., 2015b) which in turn may stimulate TGF-β 
signalling associated with an angiogenic signalling (Baumann et al., 2009). 
Unexpectedly, we observed that mainly tumor cells but not leukocytes exhibited 
phosphorylated SMAD2 (Figure 37). Previous studies have already indicated that 
pSMAD2 levels are high in glioblastoma cells, indicating that tumor cells do not have 
to escape TGF-β signalling at least at the level of SMAD2 phosphorylation (Bruna et 
al., 2007; Frei et al., 2015). However, pSMAD2 levels in B20-treated GL-261 end-stage 
tumors increased proportionally in tumor cells and leukocytes. Since the activation of 
TGF-β signalling in tumors has been linked to immunosuppression (Rich, 2003), 
increased pSMAD2 levels indicate a TGF-β-induced immunosuppressive tumor micro-
milieu during anti-VEGF treatment which might be an important factor of therapy 
failure. Yet, preliminary studies in paired human glioblastoma samples provided no 
evidence for enhanced pSMAD2 levels at recurrence, either without or with previous 
bevacizumab therapy (Figure 38;39). Nevertheless, this finding on human samples has 
to be viewed with caution, as sample size is small. Moreover, recurrent glioblastoma 
samples analysed in this small cohort may not necessarily represent the most 
aggressive tumors, since patients bearing such tumors are rarely re-operated, and thus 
biopsies are lacking. 
Limitations of the project 1 include the challenges in determining volumes of infiltrative 
rodent gliomas, the restriction to mouse models based on long-term cell lines, and the 
exploration of co-treatment rather than sequential treatments. Moreover, we did not 




VEGFR1 versus VEGFR2 signaling in mouse glioma cells, and the human patient 
cohort was small. 
This study highlights the relevance of hypoxia in the malignant phenotype of 
glioblastoma and its resistance to therapy. SMA-497 showed the highest constitutive 
level of hypoxia and was refractory to all therapeutic interventions. GL-261 eventually 
became hypoxic when escaping combination therapy (Figure 33). We conclude in 
project 1 that at least for subsets of glioblastomas, co-targeting of VEGF and TGF-β 
pathways might result in a permanent vascularization deficiency, which results in 
prolonged tumor control. Ultimately, however, such microenvironment-targeting 
therapies may only be successful if combined with pharmacological or cell-based 
therapies that exert relevant tumor cell cytotoxicity, since the major cell biological 
changes observed in selected models did not translate into major gains in survival. 
 
Findings of project 1 laid the basis to explore a new therapeutic approach in project 2. 
Recently, so far unseen responses achieved by immune checkpoint blockades in 
several therapy-refractory tumors, such as non-small cell lung cancer and metastatic 
melanoma, prompted the investigation of these agents also in glioblastoma (Preusser 
et al., 2015; Weiss et al., 2015). The clinical efficacy of these agents in glioblastoma is 
still undetermined, however, experience accumulated in other tumor entities has 
shown that a significant percentage of patients either never responds or develops 
refractory tumors. In this regard, substantial work has shown that immune checkpoint 
blockade efficacy can be improved by targeting of redundant immunosuppressive 
pathways (Wainwright et al., 2014; Twyman-Saint Victor et al., 2015; Hodi et al., 2016).  
As already mentioned, the TGF-β pathway has been attributed a central role in 
orchestrating the immunosuppressive phenotype of glioblastoma (see above). 
Therefore, we sought to determine whether inhibition of this pathway may improve the 
efficacy of PD-1 blockade in experimental glioma models. We confirmed the 
expression of PD-1 ligands by mouse glioma cell lines. PD-L1 was present on the 
surface of all cell lines, whereas this was not the case for PD-L2 (Figure 40). TGF-β 
signalling regulated neither basal levels nor induced ligand expression (Figure 40). 
Dual targeting of the PD-1 and TGF-β pathways elicited T cell responses associated 
with improved anti-tumor activity in co-culture models. Indeed, CD4+ and CD8+ T cells 
exhibited increased IFN-γ production during dual blockade compared to controls and 




also increased, yet to a lesser extent (Figure 42). Regulatory T cells are a key cellular 
components of the glioblastoma micro-environment (section 3.4.2.1).  In vitro, this cell 
population was generated only in GL-261-based co-cultures and co-treatment with 
anti-PD1 and anti-TGFβRI significantly decreased its percentage (Figure 43A). This 
may be the consequence of the crucial role played by TGF-β in eliciting FoxP3 
expression of naïve CD4+ cells and differentiation in regulatory T cells, and the ability 
of anti-PD1 antibodies to favour T cell-mediated effector responses (Chen et al., 2003; 
Fu et al., 2004; Pardoll, 2012). Also, treatment with anti-PD1 exerted a population shift 
favouring the arising of a CD8+ population over CD4+ cells (Figure 43B). 
As shown by several reports, T cell-mediated cytotoxicity of tumor cells represents the 
fundamental last step of anti-tumor immunity (Dunn et al., 2012). We found that 
combined inhibition of the PD-1 and TGF-β pathway increased lysis of GL-261 cells, 
but not in other models (Figure 43C). Intriguingly, this model was the only one where 
regulatory T cells were present and significantly decreased following targeting of PD-
1 and TGF-β signalling. It can be speculated that the reduced presence of regulatory 
T cells in the co-culture system allows for more powerful T cell effector functions 
against syngeneic tumor cells. Altogether, our findings prompt further investigations of 
dual PD-1 and TGF-β pathway blockade in vivo and these studies are currently 
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